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INTRODUCTION
The scope and depth of this review reflect the complexity
of therapy for malaria in general and of Plasmodium vivax in
particular. Even for malariologists steeped in an under-
standing of the treatment of acute, uncomplicated malaria
caused by Plasmodium falciparum, P. vivax challenges. The
tendency to fold the two species together into a single con-
ceptual framework, and they indeed share some common
ground, leads to errors in both strategic reasoning and prac-
tice with therapies. These two species are biologically and
clinically distinct in fundamentally important ways. This re-
view attempts to draw a distinction with P. vivax in the broad
context of chemotherapies and resistance to them. This task
carries the necessity of detail permitting a grasp of thera-
peutic strategies, the problem of resistance to those thera-
pies, and an appreciation of the singular nature of these
among human malarias. The review gathers and links seem-
ingly disparate facets of biology, epidemiology, and clinical
science of the infection along with key aspects of the phar-
macology of the drugs arrayed against it. The aim is an
improved likelihood of the effective application of science
against these parasites, which are responsible for so much
human suffering.
* Mailing address: Eijkman-Oxford Clinical Research Unit, Jalan
Diponegoro No. 69, Jakarta 10430, Indonesia. Phone: 62-21-391-0414.
Fax: 62-21-3190-5016. E-mail: kbaird@eocru.org.
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VIVAX MALARIA
A Neglected Infection
The perception of vivax malaria as infecting relatively few
people, causing a benign course of disease, and being treatable
with widely available therapies largely explains the almost com-
plete neglect of this important infection (20). The two frontline
drugs, chloroquine and primaquine, are each more than 50
years in service, their mechanisms of activity against the par-
asite are not understood, and standardized means of ascertain-
ing parasite resistance to either drug do not exist despite al-
most 20 years of mounting evidence of resistance (18). In the
case of primaquine against dormant liver stages, for which no
sure therapeutic alternatives exist, no clear evidence demon-
strates that the drug remains effective as prescribed (19).
Moreover, toxicity and dosing issues with primaquine severely
limit its utility in the endemic rural tropics (21).
Evidence is growing that Plasmodium vivax may infect many
more people than has been appreciated (102, 172). Evidence
also points to this supposedly benign parasite causing a spec-
trum of severe, life-threatening syndromes that are strikingly
similar to those caused by Plasmodium falciparum (20, 22, 88,
119, 172, 224). The inadequacy of the therapeutic tools to cope
with this threat encompasses the inability to gauge effective-
ness and efficacy (20). The majority of the many millions of
people infected by P. vivax this year will be treated with chlo-
roquine. The risk of treatment failure with this drug in any
more than a few areas of endemicity remains unknown. One
study in Indonesian New Guinea put that risk at nearly100%
(210), and many other studies in that region reported that it
exceeded 50% (12, 14, 15, 180, 211). Surveys in Thailand and
India, however, showed uniform sensitivity to chloroquine
(125, 136, 154, 229), except for a recent report from Gujarat in
western India, showing a 9% failure rate (209). The experience
with P. falciparum drug resistance allows a reasoned forecast of
the further deterioration of efficacy where the problem now
occurs and its encroachment toward the Indian subcontinent,
the nexus of the global burden of vivax malaria. The establish-
ment of chloroquine-resistant vivax malaria in that region
seems likely to occur well before any effort to field a vaccine
against this parasite, severely stunted in development relative
to falciparum malaria, yields such a tool.
Global Burden
Plasmodium vivax stands alone in its geographic versatility
among the other four species of plasmodia infecting humans.
Plasmodium malariae, Plasmodium ovale, and Plasmodium
knowlesi do not now occur beyond the tropics, and P. falcipa-
rum does so only sporadically. Endemic P. vivax occurs
throughout the tropical latitudes, excluding the South Pacific
east of Vanuatu, where anopheline mosquitoes do not appear,
and most of western and central Africa, where the absence of
Duffy factor on human red blood cells apparently prohibits this
parasite from an endemic distribution (63). Vivax malaria ex-
tends well beyond the tropics, through most of eastern China
up to and including the Korean Peninsula. It occurs all along
the tropical and temperate southern fringe of Asia, reaching
to the Mediterranean Sea. Figure 1 illustrates this distribution.
The sporogonic development of P. vivax in anopheline mos-
quitoes cannot occur at temperatures below 15°C, and lati-
tudes having summer isotherms near this limit represent the
most likely limits of its biologically possible range (51). Ac-
cording to Guerra and colleagues, 2.6 billion people live at risk
of infection by P. vivax (93). The estimated number of annual
clinical cases ranges from 70 million (147) to 390 million (102,
172). The overwhelming majority (probably 80%) of these
cases, whatever the actual total, occur in densely populated
South and Southeast Asia, from where mounting evidences of
both drug resistance and severe disease now emanate. Al-
though the burden of vivax malaria in the Americas is probably
relatively light, it accounts for more than 70% of malaria cases
in that region (31, 147).
FIG. 1. Biological limits of the global distribution of P. vivax based on temperature, humidity, aridity, and contemporary reports of malaria risk.
(Courtesy of Carlos Guerra, Malaria Atlas Project, Oxford University, United Kingdom.)
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A Malignant Infection
Early malariologists distinguished P. vivax from P. falcipa-
rum and P. malariae on the basis of clinical course, with P. vivax
and P. falciparum causing paroxysmal fevers at intervals of
about 48 h and P. malariae having intervals of 72 h. The first
two thus became known as tertian malaria, and the latter
became known as quartan malaria (237). The relatively perni-
cious course of P. falciparum compared to that of P. vivax
separated these two species, thus called malignant and benign
tertian malarias, respectively. The recognition of P. ovale as a
species distinct from P. vivax came decades later, and an ap-
preciation of P. knowlesi as routinely infecting humans came
only in 2007 (61). Even though malariologists have long pre-
ferred terminology applying the specific epithet of the Lin-
naean binomial species to the common name for the infection,
i.e., falciparum malaria and vivax malaria, etc. (237), the use
of the older clinical terminology persists.
The term benign applied to vivax malaria had always been in
the context of being relative to falciparum malaria. Few who
have endured vivax malaria would characterize the experience
as being benign. Fatal cases of vivax malaria, although rarely
documented, have certainly been known and should dismiss
the notion of “benign” as having been applied in any absolute
sense. Comparing relatively early stages of disease, clinical
symptoms of vivax malaria may be markedly more uncomfort-
able than those of falciparum malaria (235) and may provoke
higher levels of inflammatory cytokines per parasitized cell
(103). Nonetheless, authoritative references in medicine and
science available in 2008 asserted that P. vivax only rarely
causes death and does so by infarct or rupture of the spleen.
No text links vivax malaria with severe cerebral, pulmonary,
renal, or hepatic syndromes, but recent evidence challenges
that perspective.
The biology of P. vivax in its vertebrate host has been viewed
through the lens of almost always being relatively benign to
humans. Biological distinctions between P. vivax and P. falcip-
arum became, de facto, contrasts in the consequences of dis-
tinct parasitism strategies employed by the plasmodia in hu-
mans. The casting of contrasted consequences of falciparum
and vivax malarias provided a useful analytical lever. The pres-
ence of a trait in falciparum malaria and its absence from P.
vivax made it suspect as a determinant of disease severity.
Likewise, shared characteristics were often disqualified as de-
terminants of severe disease. The utility of this lever, and the
dogma derived from it, would be doubtful if evidence emerged
to demonstrate a spectrum of severe disease syndromes among
patients with vivax malaria resembling that among patients
with falciparum malaria.
Observations from the field within the past 5 years indeed
challenge the notion of vivax malaria as being a rare and
fastidious killer. Reports of vivax malaria marked by delirium,
seizures, renal failure, shock, hepatic dysfunction, severe ane-
mia, lung injury, pulmonary edema, and acute respiratory dis-
tress have come from South and Southeast Asia, the Middle
East, and South America (23, 24, 36, 108, 120, 122, 128, 131,
139, 140, 146, 149, 150, 160, 170, 181, 182, 193, 206, 208, 215,
216, 222, 225, 228, 240), including one case of Plasmodium
ovale (182). Some of those reports (24, 36, 128, 139, 170, 193,
206, 240) applied PCR diagnostics to rule out cryptic or mis-
diagnosed falciparum malaria infection of these patients, and
some effectively ruled out other infectious agents. Another
study reported bacteremia with Salmonella as being the pri-
mary cause of fever, shock, jaundice, and renal failure in a
patient with concurrent vivax malaria (168). Splenic rupture or
infarct with vivax malaria indeed occurs (89, 116, 159, 161) but
is either very rare or poorly represented in the medical litera-
ture.
The only recent application of PCR technology to discrim-
inate causes of malaria in endemic settings represents the
lynchpin unhinging the conviction that vivax malaria very
rarely causes life-threatening disease. Clinicians treating pa-
tients for delirium, coma, seizures, respiratory distress, renal
failure, or jaundice caused by malaria would have great diffi-
culty drawing upon any training or text to support a diagnosis
of vivax malaria. Reliable microscopic diagnostics, even if
available, would rarely discourage the diagnosis of falciparum
malaria. The ability to rule out falciparum malaria by using
PCR technology eliminates the default assumption of P. fal-
ciparum parasites being present but sequestered within the
deep organs of such patients. An urgent need exists for gross
and histological postmortem examinations of patients dying
with a diagnosis of vivax malaria.
Vivax malaria seems to cause severe disease syndromes that
closely resemble those historically attributed to falciparum ma-
laria. The rare clinicians having both the luxury of diagnostic
certainty and experience with the malarias may assert the rel-
atively benign nature of vivax malaria with respect to the like-
lihood of fatal outcomes. This represents what likely amounts
to a unique perspective, i.e., that of vivax malaria among oth-
erwise healthy people experiencing a rare or singular event. In
the broader view of endemic vivax malaria occurring almost
universally among people lacking access to even modest clini-
cal investigation capacities, patients may present constellations
of genetic, immunological, nutritional, and coinfection factors
leading to a lethal course of infection. The challenge for the
science of clinical malaria is to understand the circumstances
under which vivax malaria turns deadly, and this may well
include the problem of resistance to therapies.
Natural History
The tenacity of vivax malaria in temperate areas like the
Korean Peninsula, with long frigid seasons incapable of sup-
porting mosquitoes, lies in its ability to place dormant stages in
the liver. When an infected anopheline mosquito bites a hu-
man, typically dozens of sporozoites traffic to the liver and
probably most eventually take up residence in hepatocytes.
Unlike all of the other human plasmodia except P. ovale, a
largely unknown and probably variable fraction of those par-
asites develop into a quiescent hypnozoite rather than an ac-
tively dividing tissue schizont. The active primary tissue schi-
zont matures in about 7 days, and the release of merozoites
into the bloodstream prompts the onset of acute malaria, usu-
ally within a few days. The hypnozoite, taking an unknown
later cue, blooms into an actively dividing tissue schizont with
the same consequences of bloodstream infection and clinical
malaria, called a relapse (124). Figure 2 illustrates the life cycle
of P. vivax.
The timing and risk of relapse vary with local climate. Strains
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from areas having seasons that are inhospitable to anopheline
mosquitoes tend to relapse infrequently, at long intervals,
and only once. The timing of relapse seems to correspond
to the seasonal local abundance of anophelines. In other words,
the dormant parasite launches itself into the bloodstream when
the odds favor encountering a feeding anopheline where sexual
recombination can occur. That event marks the anopheline
mosquito as the definitive host of plasmodia. Humans, as in-
termediate hosts, serve merely as a vessel for mitotic amplifi-
cation that improves the odds of infecting another mosquito.
At one extreme of climate, P. vivax in Northern Asia (perhaps
a subspecies and called P. vivax hibernans) lacks a primary
bloodstream parasitemia. It emerges into the bloodstream only
after 1 year, almost certainly as a result of the selection pres-
sure exerted by the extraordinarily brief opportunity for
anopheline mosquitoes to exist in that climate. A well-charac-
terized North Korean strain of P. vivax represents this type
(198). The period may be too brief for achieving sexual recom-
bination, sporogonic development, and infection of yet another
human in whom the parasite may survive through a long win-
ter. At the other extreme of climate is a tropical Asian strain
like P. vivax Chesson from perpetually warm and wet New
Guinea. This parasite relapses quickly (about 18 days from the
onset of primary parasitemia) and three or more times at brief
intervals of a few weeks (47). There is no temporal window of
anopheline abundance through which parasites in New Guinea
must pass. Thus, in cooler-temperature latitudes, promiscu-
ously relapsing parasites were likely eliminated by the absence
of a suitable invertebrate host, and strains programmed for
discrete, well-timed relapse prevailed. There are no known
extrinsic cues for plasmodia to relapse, and tropical strains
evaluated in temperate climates follow their apparently intrin-
sically programmed relapse behaviors.
If one considers disease to be the defining event of infection,
the hypnozoite may be considered a reservoir of new infection
rather than a dormant old infection. One study in Papua New
Guinea (115) presented evidence suggesting that the hypnozo-
ite represented the overwhelmingly dominant source of new
parasitemias relative to new infections (21). Chemotherapeutic
attack on the hypnozoite thus resembles conventional malaria
control measures aimed at reducing new infections, i.e., those
minimizing human contact with anopheline mosquitoes by ap-
plying indoor residual insecticide spraying and bed nets, etc.
Malaria control and certainly eradication strategies failing to
recognize the hypnozoite as a source of new parasitemias may
meet with little success. This view emphasizes the central im-
portance of treatment and drug resistance in vivax malaria with
regard to strategies for controlling its transmission.
Relapse profoundly impacts strategies for the prevention,
treatment, and control of vivax malaria. It imposes the neces-
sity of two classes of drugs: (i) treatment of acute malaria and
(ii) elimination of the liver stages to avoid subsequent relapse.
Relapse also imposes nagging ambiguities in understanding
therapeutic efficacy and drug resistance, a problem severely
compounded by the failure to adapt this parasite to continuous
culture. In vitro culture systems would permit direct and ob-
jective assessments of drug activity against well-characterized
strains of the parasite, but in the absence of these tools, such
assessments must be done using more difficult, costly, and
sometime ambiguous ex vivo and in vivo systems.
THERAPY OF VIVAX MALARIA
Malaria Chemotherapeutics
The unique terminology of malaria chemotherapeutics re-
flects complexities in describing classes of drugs targeting spe-
cific stages of the plasmodia. In general, a single therapeutic
regimen of an antimalarial drug targets only a single segment
of the life cycle of the parasite. For example, mefloquine is
administered against asexual blood stages, and other drugs
must be administered against sexual blood stages and asexual
liver stages. Some drugs, however, exhibit a broader spectrum
of activity and may serve a dual purpose; e.g., a therapeutic
regimen of primaquine aimed at asexual liver stages will also
serve to neutralize mature extant sexual gametocytes and pre-
vent transmission to mosquitoes. However, a regimen of pri-
maquine aimed only at the sexual blood stages (a single 45-mg
FIG. 2. Compartments of antimalarial activity shown within the life
cycle of P. vivax. At left, a mosquito ingests infectious gametocytes,
which become infectious sporozoites. This sporogonic arm of the cycle
may be attacked with drugs called sporontocides. Sporozoites invade
the liver and become either dividing tissue schizonts or a dormant
hypnozoite that later becomes another dividing tissue schizont. This
arm of the cycle may be attacked with tissue schizontocides and hyp-
nozoitocides. The tissue schizonts release merozoites into the blood,
and these infect red blood cells and commence growth into trophozo-
ites, dividing and producing mature schizonts full of merozoites that
are capable of invading still more red blood cells. This arm of the cycle,
which is responsible for clinical malaria, can be attacked with blood
schizontocides. Some merozoites from the liver that invade red blood
cells do not become asexual blood schizonts but instead differentiate
into male and female sexual forms called gametocytes. The infectious-
ness of gametocytes to mosquitoes may be attacked with drugs called
gametocytocides. P.e., pre-erythrocytic. (Courtesy of Wallace Peters
and Andrea Darlow.)
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dose) is inadequate to effect a cure of liver stages. The stage
specificity of drugs may also vary with species of plasmodia;
e.g., therapeutic doses of primaquine (aimed at asexual liver
stages) also kill the asexual blood stages of P. vivax (175) but
not those of P. falciparum (11). Likewise, chloroquine (aimed
at asexual blood stages) also neutralizes the infectivity of ma-
ture P. vivax gametocytes to mosquitoes (111) but not those of
P. falciparum (35). These examples illustrate the necessity of
considering therapeutic intent, dose, species, and stage tar-
geted in classifying a specific drug among classes of antima-
larials.
Table 1 lists the classes of antimalarials and their essential
characteristics, and Table 2 lists and defines the terminology
often used in the context of malaria chemotherapeutics. When
malariologists refer to a radical cure of vivax or ovale malaria,
they infer the application of two or more drugs aimed at the
elimination of blood and tissue stages of plasmodia. A radical
cure of falciparum or malariae malaria can be achieved with a
single drug. Suppressive and causal prophylactic antimalarials
refer to the prevention of malaria using blood schizontocides
or tissue schizontocides, respectively. A suppressive prophylac-
tic does not prevent the root cause of clinical malaria, infection
of the liver, whereas a causal prophylactic does. Travelers
taking suppressive prophylaxis are often directed to take a
standard course of primaquine therapy aimed at liver stages in
order to prevent the subsequent relapse of vivax or ovale ma-
laria. This treatment is often called prophylaxis, but the term
presumptive antirelapse therapy is preferred (105).
Another set of important terms often used by malariologists
bears directly upon therapy. The biology of the term relapse
has been explained as an acute blood-stage infection originat-
ing from a hypnozoite. This term contrasts with parasitemias
originating from reinfection or recrudescence. These terms
represent the three possible sources of patent blood-stage in-
fection following therapy of a primary parasitemia. Reinfection
obviously represents an event arising from a separate exposure
to mosquitoes carrying sporozoites. Recrudescence describes
the patency of blood stages driven to subpatency and subse-
quently reappearing. Another term is often applied to describe
patency following treatment: recurrence. This term is deliber-
ately ambiguous with respect to the origin of the parasitemia,
and it is applied when the source of a new parasitemia is
uncertain.
Chloroquine Therapy
Chloroquine has been the therapy of choice for the treat-
ment of acute vivax malaria since 1946 (151). Developed as
resochin in the 1930s, its German developers abandoned the
drug in favor of a seemingly less toxic methylated analog called
sontochin. The U.S. Army obtained experimental sontochin
tablets in Algeria during late 1943 and almost immediately
TABLE 1. Classes and representative antimalarial drugsa
Type of drug Target Clinical application Prophylaxis Licensed drug(s) Experimental drug(s)
Blood schizontocide Trophozoite in blood Treatment of acute
malaria
Suppressive Chloroquine, quinine,
mefloquine, doxycycline,
AV-PG, DH-PP
Tafenoquine, ACTs
Primary tissue
schizontocide
Active schizont in liver None Causal Primaquine Tafenoquine
Hypnozoitocide Dormant hypnozoite
in liver
Prevention of relapse None Primaquine Tafenoquine, elubaquine
Gametocytocide Gametocyte in blood Prevention of transmission None Primaquine Tafenoquine, artesunate,
artemether
Sporontocide Forms in mosquito
including sporozoite
Prevention of transmission Causal prophylaxis Primaquine Tafenoquine
a AV-PG, atovaquone-proguanil (Malarone); DH-PP, dihydroartemisinin-piperaquine (Artekin); ACTs, artemisinin combined therapies (many in evaluation).
TABLE 2. Malaria chemotherapeutic terminology
Term Definition
Blood schizontocides .............................................Drugs aimed at asexual blood-stage parasites to effect a cure of clinical malaria
Primary tissue schizontocide ................................Drug aimed at primary asexual liver-stage parasites to prevent primary blood infection
Hypnozoitocide ......................................................Drugs aimed at latent asexual liver-stage parasites (hypnozoites) to prevent recurrent infection
of blood, called a relapse
Gametocytocide......................................................Drugs aimed at sexual blood-stage parasites to prevent infection of mosquitoes
Sporontocide...........................................................Drug aimed at stages of sporogonic development in the mosquito, including sporozoites
Radical cure............................................................Elimination of clinically relevant forms of the parasite from the body using one or more drugs
Suppressive prophylaxis.........................................Chemical suppression of patent parasitemia by a drug or drugs that are active against asexual
blood stages
Causal prophylaxis .................................................Prevention of infection of blood with a drug or drugs that are active against asexual liver stages
Presumptive antirelapse therapy..........................Presumptive treatment with a hypnozoitocide following exposure to infection, also called
terminal prophylaxis
Relapse....................................................................New parasitemia originating from hypnozoites
Reinfection .............................................................New parasitemia originating from new infectious mosquito bite
Recrudescence........................................................New parasitemia originating from the original parasitemia
Recurrence..............................................................New parasitemia of unknown origin
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discovered resochin among patent archives registered by
Winthrop Chemical Company in New York, NY, cartel partner
to the German manufacturer (Bayer, then a subsidiary of IG
Farben). Both drugs went to rushed wartime clinical trials, and
resochin, renamed chloroquine by the Americans, emerged as
the superior drug (50).
The recommended adult treatment was 25 mg/kg body
weight administered in 3 doses over 48 h (typically 10 plus 10
plus 5 mg/kg at 24-h intervals). A 60-kg adult would thus
consume a total dose of 1.5 g chloroquine base. However, this
total dose far exceeded the minimal effective dose against P.
vivax at that time. A series of experiments decisively demon-
strated that total adult doses as low as 0.3 g consistently cured
parasitemias of vivax malaria (27, 238). The developers of
chloroquine nonetheless recommended the same dose for all
malarias.
Chloroquine was, in almost all ways, the perfect drug for
treating acute malaria in endemic settings. It was cheap, uni-
versally effective against all plasmodia species, deliverable over
a brief period in few doses, and safe even for pregnant women
and small children and came with few side effects. No drug like
this had appeared before, and none like it has appeared since
with these uniformly superior characteristics for a drug put to
work in areas where medical supervision rarely occurs (60).
Whenever and wherever resistance to chloroquine prompts its
withdrawal from service, the drug that replaces it will be more
expensive and more difficult to administer, the safety for preg-
nant women and small children will be less certain, and it may
cause more marked side effects. No drug now available equals
the overall effectiveness of chloroquine in the heyday of its now
nearly vanished efficacy. The artemisinins may eventually rival
chloroquine in this regard but only after conclusive demonstra-
tions of safety for pregnant women and after market compe-
tition and industrial innovation drive down the cost and com-
plexity of dosing.
Historically, chloroquine clears fever and parasitemia caused
by P. vivax within, at most, 72 h of the first dose. The drug is
very rapidly absorbed and slowly eliminated, principally as a
parent drug and a desethyl metabolite in roughly 3:1 propor-
tions (143). The plasma half-life is about 50 h, and therapeutic
levels against vivax malaria persist in blood until about days 21
to 35 after the start of treatment (46, 132). In contrast, quinine
is almost completely eliminated within 24 h of dosing (239).
This difference in these two drugs has important implications
for an understanding of the assessment of the therapeutic
efficacies of both chloroquine and primaquine.
Figure 3 illustrates recurrent parasitemia after chloroquine
or quinine therapy among subjects with vivax malaria acquired
in 1940s tropical Asia or experimentally induced by challenge
with sporozoites of the Chesson strain of P. vivax from New
Guinea (18). Efficacy against blood stages has no bearing upon
the difference in the shapes of these two curves. Instead, the
pharmacokinetics of each respective drug and the impact upon
relapse shape these curves. The postquinine recurrent para-
sitemias are known to be relapses because the same doses
administered to subjects challenged with blood stages rather
than sporozoites showed no recurrences (239). Whereas rap-
idly eliminated quinine allows essentially unfettered relapse,
slowly excreted chloroquine eliminates new parasites emerging
from the liver until, at about day 35, it finally falls below
therapeutic levels, and emerging parasites survive to manifest
patent parasitemia. The slow excretion and persistent activity
of chloroquine in the blood represent the primary analytical
tool for the classification of infections as being chloroquine
sensitive or resistant, as shown by the 1995 postchloroquine
recurrences in Fig. 3 (see Resistance to Chloroquine below).
Primaquine Therapy
Pamaquine (also called plasmochin) was an 8-aminoquino-
line with the curious property of preventing the as-yet-not-
understood process of relapse when discovered in the Elber-
feld laboratories of Bayer in the 1920s in Germany (92). The
drug proved to be too toxic for clinical use in humans, and only
limited commercial distribution occurred. The strategic urgen-
cies of the Second World War sparked a vigorous effort to
discover a less toxic replacement. Primaquine, another 8-amino-
quinoline, emerged from the same war-spurred program as
chloroquine but was identified through a systematic survey of
many hundreds of 8-aminoquinolines in birds and nonhuman
primates. Eighteen candidates advanced to clinical trials. All of
them seemed to be effective against relapse, but 8-aminoquino-
line toxicity limited therapeutic choices (4). Primaquine had
the highest therapeutic index and moved to licensure, produc-
tion, and rushed use for American troops at war on the Korean
Peninsula in 1950 (32).
In the earliest clinical trials of primaquine, investigators
noted hemolytic anemia among African American subjects (65,
106) and ultimately discovered glucose-6-phosphate dehydro-
genase (G6PD) deficiency (37), an inherited blood disorder
linked to a survival advantage against falciparum malaria
(190). Occurring at the q28 locus on the X chromosome, about
200 variant alleles have been described, with residual enzyme
activities ranging from 0% to almost 100% (28). Heterozygous
females often have mixed populations of normal and deficient
red blood cells. The clinical consequences of G6PD deficiency
and drug-induced hemolytic anemia range from mild and tran-
FIG. 3. Deterioration of chloroquine (CQ) efficacy between 1945
(green line) and 1995 (red line) among tropical Asian strains of P. vivax
relative to natural relapse of the same strains following quinine (QN)
therapy (blue line). The suppression of relapse by chloroquine in 1945
is due to lingering levels of drug in blood up to day 35, and the 1995
data suggest not only failure to suppress relapse but also failure to
clear primary asexual parasitemia. Data were derived from various
sources (12, 18, 47, 210, 239).
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sient to severe and life-threatening. In general, residual en-
zyme activity correlates with the severity of reactions to hemo-
lytic drugs (29). Among African A variants, primaquine-
induced hemolysis tends to be mild and self-limited, apparently
capable of destroying only senescent red blood cells. A
G6PD-deficient subjects given primaquine relatively quickly
recovered normal hematocrit levels, even in the face of con-
tinued standard therapy of 15 mg daily (7). The 45-mg weekly
dose over 8 weeks was developed for safe and tolerable use in
A G6PD-deficient patients (200), but the safety of this regi-
men among the many other variants has not been established
and is rarely recommended.
Primaquine usually comes available as tablets containing 15
mg base. Most manufactured tablets cannot be reliably cut, and
clinical literature on the drug typically refers to adult doses in
15-mg increments, i.e., 15- or 30-mg daily doses or 45-mg
weekly doses (105). Studies by Schwartz et al. (200) and by
Duarte et al. (70) demonstrated a higher risk of failure among
heavier patients given the standard 15-mg daily adult dose for
14 days. An administration of a total dose of 3.5 mg/kg (or
0.25 mg base/kg body weight daily for 14 days) for small chil-
dren and heavy adults was thus recommended. Most authori-
ties now recommend 0.5 mg/kg daily for 14 days (105). In
practice, however, the practitioner must choose between daily
doses of 15 mg, 30 mg, and 45 mg among patients of most sizes.
Doses of 15 mg for patients weighing 20 kg to 40 kg, 30 mg for
those weighing between 41 kg and 70 kg, and 45 mg for those
weighing 70 kg delivered doses ranging from 0.37 to 0.75
mg/kg up to 100 kg body weight. Patients weighing 20 kg
often receive dosing approximated by manual crushing of tab-
lets and delivery in liquid. Dosing in this review adheres to that
predominating in the literature, with reference to the daily
dose in milligrams base delivered to an adult weighing 41 to
70 kg.
The standard adult regimen of primaquine for the preven-
tion of relapse was, until recently, 15 mg daily for 14 days.
Some alleged that this regimen reflected the shipboard transit
time from Korea to the United States for returning U.S. sol-
diers. However, the more likely genesis of this relatively incon-
venient regimen may be found in the tolerance studies done by
Clayman and colleagues using prison inmate volunteers (42).
They administered single doses of primaquine ranging from 5
to 215 mg to fasted subjects and measured the frequency and
intensity of gastrointestinal upset. Almost none complained
with the 5-mg dose, and the 215-mg dose caused “immediate
and severe cramping.” The 15-mg dose prompted complaints
from only 10% of subjects, whereas the 30-mg dose caused
30% of subjects to complain. The idea that exceeding the
15-mg dose caused unacceptable intolerance and toxicity took
hold among malariologists and severely limited the useful ap-
plication of this otherwise extremely versatile drug. The view
on primaquine toxicity expressed by the prominent malariolo-
gist David F. Clyde (45) represented the broader-held view-
point that, “… the fact that the therapeutic dose and the toxic
dose are close leads to serious problems associated with its
use.”
During the early 1990s, an effort to develop an in vivo test
procedure for chloroquine-resistant P. vivax led to experimen-
tation with primaquine as a means to suppress the confounding
of that test by reinfection and relapse. A clinical trial of pri-
maquine for this purpose applied 30 mg every other day, and it
was found to be as well tolerated as chloroquine prophylaxis
(13). Those authors cited the seminal paper on primaquine
tolerability by Clayman et al. (42) and described a rarely cited
aspect of that early study: when primaquine was administered
with food (rather than fasted), the prisoner volunteers who
took “even the highest doses” of primaquine (presumably 215
mg) registered no complaints. Food greatly improved the tol-
erability of primaquine and emboldened subsequent random-
ized, double-blind, placebo-controlled trials of 30 mg prima-
quine daily lasting from 11 to 50 weeks (16, 79, 234). In those
trials, primaquine was as well tolerated as placebo. These stud-
ies in turn likely emboldened authorities to recommend 30 mg
daily for 14 days as the standard adult dose for primaquine
therapy.
Primaquine therapy against liver stages exhibits an unusual
and poorly understood phenomenon referred to as the total
dose effect. In both preclinical and clinical trials, the total dose
of primaquine seemed to be the key determinant of efficacy
regardless of the duration over which the dose was adminis-
tered. In 1977, Schmidt et al. (197) carefully described the
effect using rhesus monkeys infected by Plasmodium cynomolgi
(a P. vivax-like parasite with hypnozoites and relapse behav-
iors). In their experiments, they administered a therapeutic
dose of primaquine with an effective companion drug (chloro-
quine or quinine) as a single dose or as daily doses adminis-
tered over 3, 7, or 14 days: all showed equally good efficacies
against relapse. Clinical trials demonstrated the same phenom-
enon at work with vivax malaria. In 1977, Clyde and McCarthy
(44) described 11 human subjects experimentally challenged
with P. vivax Chesson and given 30 mg daily for 7 days instead
of 14 days, and none relapsed. The weekly administration of 45
mg primaquine for 8 weeks with good efficacy against relapse
demonstrates the total dose effect even more dramatically (7).
The perception of toxicity and poor tolerability for higher daily
doses (15 mg) of primaquine limited the exploitation of such
versatility. Indeed, Clyde and McCarthy (44) concluded their
abstract with, “However, it is stressed that because of the risk
of primaquine-induced hemolysis in individuals having genet-
ically transmitted erythrocyte abnormalities this high dosage
[30-mg daily adult dose] should not be used routinely.” Such
viewpoints suppressed the opportunity to explore more prac-
tical (higher-dose, shorter-duration) regimens of primaquine.
The 14-day dosing regimen of primaquine almost certainly
diminishes its effectiveness. In many countries in zones of en-
demicity, a 5-day regimen (15 mg daily) of primaquine was
adopted and used for decades both on the basis of evidence
from poorly controlled clinical trials and in an effort to improve
effectiveness (19). That regimen was later proven to lack effi-
cacy, and the practice has been largely abandoned. The safety,
tolerability, and efficacy of primaquine administered in twice-
daily doses of 60 mg base over 3 days should be explored for
use in people with access to screening for pregnancy and G6PD
deficiency (17).
Primaquine may not be effective against liver stages unless it
is administered with another drug. As early as 1955, Alving and
colleagues (6) asserted this with a standard 15-mg daily dose
(14 days) against P. vivax Chesson, with one treatment group
receiving quinine therapy before starting primaquine therapy
and the other group receiving the two therapies concurrently.
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The relapse rates among these two groups of 19 human sub-
jects each after 6 to 12 months of follow-up were 95% and
21%, respectively. Edgecomb et al. (73) did this experiment
using the 30-mg daily dose without and with concurrent qui-
nine and reported relapse rates of 80% and 3%, respectively.
Essentially similar findings were made in clinical trials of pam-
aquine and quinine during the 1940s. Berliner and colleagues
(26) found that 90 mg pamaquine (daily for 14 days) given
concurrently with standard quinine therapy provided 100%
efficacy against relapse of the Chesson strain, but when the
same regimen was applied serially (quinine followed by pam-
aquine), all subjects relapsed. Craige et al. (62) saw a similar
effect when applying a less efficacious 63-mg daily pamaquine
regimen against the Chesson strain. According to Schmidt
(195), challenge studies done by the U.S. National Institutes of
Health at the Stateville Penitentiary in 1949 applied penta-
quine in combination with quinine and achieved cure for 8 of
11 subjects. However, when the same dose of pentaquine was
administered with chlorguanide rather than quinine, only 1 in
10 subjects was cured. Schmidt (195, 196) found essentially
similar findings with Plasmodium cynomolgi infection of rhesus
macaques. These experimental outcomes, most reported over
50 years ago, elicit incredulity today. Primaquine monotherapy
has been viewed as being effective against hypnozoites because
the practical importance of all of these studies was forgotten
with the deployment of primaquine and chloroquine as first-
line, companion therapies for the radical cure of vivax malaria.
These studies are conspicuously relevant today. New blood
schizontocides supplanting chloroquine as frontline therapy
for acute vivax malaria would thus represent new companion
drugs for primaquine. The same is true for new drugs aimed
at hypnozoites, especially the 8-aminoquinoline candidates.
These studies illustrate the necessity of gauging the impact of
companion blood schizontocide upon the efficacy of the hyp-
nozoitocide against relapse.
Experimental Therapies
Drug development strategy. The availability of blood schi-
zontocides for vivax malaria has been dependent upon drugs
developed for falciparum malaria. Drugs in advanced develop-
ment, or even postmarketing, are typically then applied to
vivax malaria in either nonhuman primate studies or in clinical
trials. This approach presents obvious advantages, especially in
the vital stretch of early drug development that includes in
vitro screening of candidate drugs for efficacy against blood
stages. A similar high-throughput screening specific for vivax
malaria remains impractical in the absence of a system of
continuous in vitro cultivation. Fortunately, the pipeline for
blood schizontocides against falciparum malaria has rarely
failed with vivax malaria. Almost every drug licensed for fal-
ciparum malaria in the past 60 years has also proven to be safe
and effective for the treatment of acute vivax malaria, with the
exception of sulfadoxine plus pyrimethamine (SP) (widely mar-
keted as Fansidar). Even that exception may have been a
misperception (see Resistance to Antifolates below). Chloro-
quine, mefloquine, halofantrine, piperaquine, and the arte-
misinins all proved to be effective against acute vivax malaria.
Until P. vivax becomes successfully adapted to continuous in
vitro cultivation, this shared approach of drug discovery will be
applied.
The early work of Alving and colleagues (6, 26, 62, 73)
showed that primaquine apparently required an appropriate
companion drug to effect the elimination of hypnozoites. This
consideration adds substantial technical complexity to the de-
velopment of therapies for vivax malaria. The development of
blood and tissue schizontocides/hypnozoitocides within inde-
pendent tracks has been the dominant approach. The isolation
of these therapeutic targets appeals to technical sensibility, but
it may also impose unappreciated hazards. Should the inter-
pretation of the data reported by Alving and colleagues (6, 26,
62, 73) prove true, the segregated development of blood and
tissue schizontocides would risk fielding blood schizontocides
that leave primaquine (or another hypnozoitocide) impotent
against hypnozoites. Likewise, that approach imposes a risk of
losing entire families of drugs against hypnozoites by failing to
screen candidates with companion blood schizontocides. Had
the discoverers of primaquine not used quinine or chloroquine
in their trials, the drug would very likely have been discarded
and lost. A direct linkage of the development of blood and
tissue therapies against vivax malaria may be required to avoid
these risks. Coping with that development strategy requires
overcoming technical, logistical, and regulatory challenges.
Hypnozoitocides. The neglect of clinical trials evaluating
hypnozoitocidal drugs very likely reflects the relative difficulty
of such work. The rational analysis of such trials requires both
a relative abundance of naturally infected study subjects and
their willingness or availability for long-term follow-up and
without risk of reinfection. This last requirement rules out an
area of endemicity, whereas the first requirement demands an
area of endemicity, a formula of mutual exclusion leaving few
opportunities for meaningful work. Nonetheless, such studies
are possible with travelers who acquire vivax malaria and re-
turn to a nonendemic area. Soldiers, migrant workers, or tour-
ists may serve as likely study populations in urban research
centers. Mahidol University’s Hospital for Tropical Diseases in
Bangkok, Thailand, has employed this strategy, and its produc-
tivity in clinical research of 8-aminoquinolines against liver
stages demonstrates feasibility. Nonetheless, few centers en-
gage in such research because its vital importance to patient
and public health has not been adequately appreciated. The
experimental challenge data from the clinical screening of
8-aminoquinolines during the 1940s and 1950s show decisively
that follow-up to only 28 days is not adequate for assessing
clinical efficacy against relapse: more than half of drug failures
occurred beyond day 28 (4).
A notable exception to the broad neglect of hypnozoitocides
has been the development of tafenoquine as the intended
successor to primaquine for the prevention of relapse (165).
This drug was invented by the U.S. Army and later developed
in clinical trials by GlaxoSmithKline (United Kingdom) and,
later still, by the Medicines for Malaria Venture (a consortium
of private and public agencies). The developmental path of this
drug, more tortuous than most, included an initial indication
for prophylaxis only (32). It is currently being developed as an
antirelapse drug (232). Tafenoquine exerts an extraordinarily
broad spectrum of activity against blood and tissue stages of P.
falciparum and P. vivax, killing liver-stage schizonts and hyp-
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nozoites, sexual and asexual blood stages, and stages in the
mosquito host (52, 157, 164, 169). The long plasma half-life of
this 8-aminoquinoline (14 days) contrasts with the very rapid
elimination of primaquine (half-life of 4 h) and provides inci-
dental prophylactic protection lasting for several months (201).
Its utility as a potential tool for malaria elimination should be
conspicuous: in concept, a single course of therapy could elim-
inate disease, relapse, and further transmission. Moreover, this
treatment could eventually eliminate the infection of mosqui-
toes by virtue of a period of effective prophylaxis extending
beyond the lifetime of most anopheline mosquitoes. Perhaps
the greatest challenge with tafenoquine for any broad thera-
peutic application is the likelihood of hemolytic toxicity in
G6PD-deficient people, a safety challenge exacerbated by its
very long plasma half-life.
Another experimental therapy, elubaquine (formerly known
as bulaquine), has shown promise as a hypnozoitocide (72).
Elubaquine is a prodrug of primaquine invented at the Central
Drug Research Institute, India. It is rapidly metabolized to
primaquine and exhibits most of primaquine’s pharmacoki-
netic characteristics (145). The two drugs showed similar effi-
cacies against relapse in a limited number of trials, each with
inherent limitations. In a study in Thailand (126), follow-up
occurred only to day 28, and a study in India (1) applied a
suboptimal 5-day regimen. Nonetheless, in these limited stud-
ies, elubaquine showed performance at least equal to that of
primaquine in preventing relapse. Comparisons of safety
proved to be much more interesting in the Thai study: among
four subjects with G6PD deficiency treated with primaquine,
all experienced significant drops in hematocrit levels (a mean
of 39% on day 1 to a mean of 21% on day 8), whereas none of
the three G6PD-deficient subjects treated with elubaquine did
so (126). If elubaquine proves as efficacious as primaquine and
yet somehow does not cause hemolytic anemia in G6PD-defi-
cient subjects, its value in attacking endemic vivax malaria
would be enormous.
Blood schizontocides. An assessment of experimental ther-
apies for acute vivax malaria requires grappling with the am-
biguities imposed by relapse. Table 3 represents a wide range
of clinical data available on largely experimental therapies for
acute vivax malaria. Studies are segregated into three broad
categories according to the withholding of primaquine from
combined therapeutics, its application with either mono- or
combined therapies, or its withholding from monotherapies
(Table 3). Cure rates are given for day 7 and day 28 following
the start of therapy, and the reason for doing so should be
obvious by an examination of outcomes in Table 3. Drugs such
as artesunate, artemether, halofantrine, and quinine show ex-
cellent efficacy at day 7 but uniformly poor efficacy at day 28.
In contrast, primaquine, chloroquine, piperaquine, and meflo-
TABLE 3. Therapies for acute vivax malaria with and without primaquinea
Therapy Location No. of subjects Randomized
% Efficacy
Reference
Day 7 Day 28
Without primaquine
SPAS Afghanistan 90 Yes 100 96 121
DHPP Indonesia 90 Yes 99 98 179
LFAR Indonesia 85 Yes 99 89 179
AQSPb PNG 98 Yes 89 142
SPASb Indonesia 19 Yes 100 100 223
With primaquine
AS Vietnam 28 No 100 96 64
AS Thailand 299 Yes 100 100 203
RF Thailand 5 Yes 0 0 173
MQ Indonesia 295 Yes 100 100 138
AZ India 97 Yes 84 88 71
DHPPc Indonesia 54 Yes 98 96 99
AQASc Indonesia 60 Yes 97 92 99
DHPPc Indonesia 83 Yes 100 100 171
Without primaquine
AS Thailand 316 Yes 50 203
AS Thailand 20 Yes 100 40 175
AR Thailand 20 Yes 100 48 175
HF Thailand 23 Yes 100 40 175
QN Thailand 22 Yes 100 48 175
PQ Thailand 30 Yes 100 96 175
CQ Thailand 30 Yes 100 100 175
MQ Thailand 20 Yes 100 100 175
SP Thailand 12 Yes 56 28 175
TC Thailand 18 Yes 100 78 176
DX Thailand 18 Yes 100 57 176
CL Thailand 12 Yes 100 58 176
AZ Thailand 18 Yes 100 20 176
a AS, artesunate; DH, dihydrartemisinin; PP, piperaquine; LT, lumefantrine; AR, artemether; AQ, amodiaquine; PQ, primaquine; RF, rifampin; MQ, mefloquine;
AZ, azithromycin; HF, halofantrine; QN, quinine; CQ, chloroquine; TC, tetracycline; DX, doxycycline; CL, clindamycin.
b Administration or withholding of primaquine therapy not explicitly detailed.
c Unsupervised primaquine offered to study subjects after completing these therapies.
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quine show almost complete efficacy at both points. With the
notable exception of primaquine, what separates these classes
of outcomes is the plasma half-life of the therapeutic applied.
Relapses after the rapid loss of therapeutic levels of drug
appear to account for the very poor cure rates at day 28.
Likewise, the excellent cure rates with chloroquine and meflo-
quine appear to be the product of a lengthy plasma half-life
and the successful suppression of relapse. The outcomes with
primaquine tend to affirm this interpretation: it is very rapidly
eliminated and yet showed an excellent cure rate at day 28, and
its activity against relapse seems to be the most likely expla-
nation. These data also illustrate the very high risk of relapse
among subjects infected by P. vivax in Thailand: apparently
50% within 28 days of patency.
An assessment of experimental therapies in such clinical
trials thus requires a grasp of at least three important variables:
(i) the plasma half-life of the therapy applied, (ii) the presence
or absence of primaquine with therapy, and (iii) the geographic
origin of the infection being treated (risk of relapse within the
duration of evaluation). What appear to be poor therapeutic
blood schizontocidal outcomes may be entirely attributable to
relapse, as suggested by the data summarized in Table 3. On
the other hand, a very poor outcome against asexual blood
stages may be masked by relapses that are neither eliminated
(by primaquine) nor suppressed (by lengthy plasma half-life
therapies). This ambiguity limits the utility of clinical trials
compartmentalized for the examination of blood-stage infec-
tion only.
The data from Indonesia, listed in Table 3 (179), illustrate
this quandary. Those authors examined the effectivenesses of
both dihydroartemisinin plus piperaquine (DHPP) and
lumefantrine plus artemether (LFAR) against acute vivax
malaria among residents of southern Papua. Both drugs
showed very good efficacy at day 7. At day 28, 98% of subjects
taking DHPP remained free of parasites, whereas this was
true for only 89% of those given LFAR. Concluding that
DHPP was the superior blood schizontocide would be sub-
ject to error. The difference in these therapies may be the
product of successfully suppressed relapse by a relatively
longer persistence of effective levels of piperaquine in blood
than lumefantrine. Both drugs may have effected a complete
blood-stage cure, but one more successfully suppressed re-
lapse than the other, and the suppression of relapse was not
the clinical objective of either therapy. On the other hand,
one cannot rule out therapeutic failures lurking among the
late recurrences of parasitemia following LFAR treat-
ment. In the absence of a means of distinguishing relapse
from reinfection or recrudescence, identification of the su-
perior blood schizontocidal therapy remains elusive.
The inclusion of primaquine with the blood schizontocide
being evaluated partially addresses the problem of con-
founding by relapse, but it also introduces another con-
founding factor. With the exceptions of rifampin (203) and
azithromycin (173), the listed therapies showed very good
estimated efficacies against blood stages (Table 3). With the
possible exception of Thailand, however, few other areas
can offer data supporting the assumption of complete effi-
cacy against relapse by P. vivax with any given regimen of
primaquine. Moreover, primaquine itself exerts potent
blood schizontocidal activity against P. vivax (174, 175, 236).
The inclusion of primaquine therapy in evaluations of ther-
apies aimed at asexual blood stages introduces the possibil-
ity that the observed good efficacy may not be fully attrib-
utable to the blood schizontocide under evaluation.
Resolving these ambiguities with blood-stage therapies for
acute vivax malaria must await a technology that reliably dis-
criminates relapse from reinfection or recrudescence as the
source of recurrent parasitemia after therapy. Alternatively, a
distinct approach to clinical trials for vivax therapies may be
applied. Rather than attempting a dissection of blood- from
tissue-stage therapeutic effects, one may simply accept radical
cure as the sole therapeutic objective. The evaluation of ther-
apies against vivax malaria for real-world use should be com-
bined for the elimination of blood- and tissue-stage parasites.
Any recurrent parasitemia not attributable to reinfection may
be considered to be a therapeutic failure without regard to
which particular compartment failed.
In assessing the efficacy of radical cure of vivax malaria,
the period of posttherapy follow-up matters a great deal.
The data in Table 3 show a good efficacy of applied thera-
pies as a radical cure, at least within the 28 days of obser-
vation. The importance of considering the follow-up period
may be seen in the data for mefloquine shown in Table 3
(173, 175). With or without primaquine, the suppression of
early relapse may create the illusion of effective radical cure.
This will be true of any drug with a similarly long plasma
half-life. Thus, detecting relapse due to primaquine failure
in radical cure requires addressing adequate follow-up with
either no risk of reinfection or ascertained rates of reinfec-
tion for attributable risk estimations.
The ideal randomized, controlled trial of a therapy for
radical cure would measure recurrent parasitemia among
subjects not exposed to a risk of reinfection during a 1-year
follow-up. The standard and experimental therapy groups
would each be composed of sets of drugs designed to elim-
inate asexual blood and liver stages. The study would be
powered to demonstrate the noninferiority of the experi-
mental therapy with respect to safety and efficacy. The cu-
mulative incidence of recurrent parasitemia over the course
of 1 year provides the basis of comparison. The same trial in
an area of endemicity (and having a risk of reinfection
during follow-up) would require two additional treatment
arms: one to measure the incidence of reinfection (effective
radical cure control) and the other to measure the incidence
of new parasitemia due to relapse (effective blood-stage
cure only).
All of the analytical issues detailed here also apply to
assessments of standard therapies against vivax malaria, as
in gauging resistance. However, the practical option of not
segregating blood- from tissue-stage activities cannot be ap-
plied in the instance of demonstrating biological resistance
to standard therapy. A liver-stage parasite resistant to pri-
maquine may be wholly sensitive to chloroquine in the blood
stage. These effects must be segregated in order to develop
practical therapeutic strategies for coping with resistance.
A demonstration of stage-specific resistance represents
the analytical cornerstone of an understanding of the prob-
lem.
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RESISTANCE TO CHLOROQUINE
Definition
Asexual blood-stage parasites that have been demonstrated
to survive a normally absorbed standard regimen of therapy
may be classified as being resistant to that therapy. In a phar-
macokinetic sense, one typically gauges resistance against ei-
ther peak levels of drug during the course of treatment or the
area under the curve of bioavailable concentrations of drug.
For malaria, this means identifying recurrent parasitemia as a
recrudescence, but such a perspective in defining the resistance
of P. vivax to chloroquine has proven elusive. The only pub-
lished methodology detailing a means of diagnosing resistance
to chloroquine with this parasite (14) carries ambiguities im-
posed by the phenomenon of relapse and, to a lesser extent,
reinfection.
In the case of P. falciparum, recurrent parasitemia following
therapy may be either a recrudescence or a reinfection. Al-
though somewhat nuanced with respect to the possibility of
coinfecting strains and PCR sensitivities, a relatively simple
check of parasite genotypes allows classification of recurrent
parasitemia as a recrudescence (matched genotype with pri-
mary parasitemia) or reinfection (mismatched genotype)
(205). Recurrences classified as reinfections are typically dis-
counted as losses to follow-up during the 14- to 42-day fol-
low-up period (94).
In contrast, P. vivax hypnozoites essentially remove this tool
of discernment from the in vivo test format. A perfectly
matched genotype may be either a recrudescence or a clonal
relapse (40). Likewise, mismatched primary and secondary
parasite populations may represent either a new infection or a
relapse (141). Putting aside the complex issue of inbreeding
frequencies and clonal population structure (8), a single mos-
quito may carry sporozoites representing at least several geno-
types from any number of successful gamete unions (185).
Thus, a single brood of invading parasites may yield a primary
tissue schizont and patent parasitemia of genotype A and a
hypnozoite of genotype B, or the hypnozoite may be genotype
A. Even discounting the more vexing problem of dealing with
people with an accumulation of multiple broods of hypnozoites
lying dormant in their livers (47), genotyping does not now
allow discerning parasitemia originating from recrudescence,
relapse, or reinfection.
The methodology for diagnosing resistance to chloroquine
(14) dealt with this problem by sidestepping the necessity of
distinguishing recrudescence from relapse or reinfection. The
test hinges upon lingering levels of chloroquine in blood for 28
days following therapy and the minimally effective concentra-
tion of chloroquine and its major metabolite, desethylchloro-
quine (CQDCQ), in blood. By examining the graphs in Fig.
3, it may be appreciated that in the 1940s and 1950s, chloro-
quine prevented the patency of relapses up to day 35. The
contrasting postquinine recurrences represent relapses and not
recrudescences: the effective killing of blood stages by quinine
was demonstrated by the absence of posttreatment recurrences
among subjects challenged with blood stages rather than
sporozoites (239). Chloroquine or quinine alone exerts no ef-
fect upon latent liver stages (239), and the differences in their
respective excretion rates (slow versus rapid, respectively) ac-
count for the marked difference in the shapes of the post-
therapy recurrence curves. One may thus be confident that the
curve of recurrences after quinine treatment represents true
relapse and that the suppression of relapse after chloroquine
treatment represents the blood schizontocidal effect of linger-
ing drug in the blood (14). If so, the onset of recurrences at
about day 35 after chloroquine treatment should represent the
threshold at which drug levels slip below the minimally effec-
tive concentration for sensitive parasites.
Several lines of evidence supported that supposition and
helped to establish the estimated minimally effective concen-
tration of CQDCQ in whole blood, the value that ultimately
segregates sensitive from resistant phenotype classifications in
the in vivo test format. First, Berliner et al. (27) measured the
minimally effective concentration of chloroquine against P.
vivax in the 1950s, presumably when resistant phenotypes were
not more than very remotely likely to occur. Those authors
measured it at 15 ng/ml plasma, which corresponds roughly to
120 ng/ml whole blood (by multiplying by a factor of 8, derived
from several parallel measurements of the two compartments)
(2, 183). Rombo et al. (184) approached the same measure-
ment from the perspective of effective prophylaxis and derived
a value of 90 ng/ml whole blood. Finally, CQDCQ following
therapy show mean levels near 100 ng/ml at day 35, the point
at which relapses of chloroquine-sensitive parasites begin
breaking through. Taking into consideration all of these ob-
servations, the value of 100 ng/ml was selected as an estimate
of the minimally effective concentration of CQDCQ in whole
blood (14). Direct observation of this threshold should be
confirmed by measuring CQDCQ levels at the onset of re-
lapse following the treatment of chloroquine-sensitive vivax
malaria.
The diagnosis of resistance to chloroquine thus involves the
critical measurement of CQDCQ in blood on the day of
recurrent parasitemia. Whether recurrent parasitemia repre-
sents recrudescence, relapse, or reinfection is not known, but
we know that the parasite has broken through concentrations
of drug in blood that ordinarily eliminate parasites of the
chloroquine-sensitive phenotype. This currently stands as the
only functional definition of resistance to chloroquine in vivax
malaria. Other possible means of making the diagnosis (ex vivo
and animal models) along with the nuanced interpretation of
in vivo testing are detailed below.
Diagnosis
Several options exist for examining the response of P. vivax
to chloroquine: the 28-day in vivo test, ex vivo assays, and
animal model systems. Each of these is detailed here.
Twenty-eight-day in vivo test. The rationale for the 28-day in
vivo test is detailed above. This section focuses on the conduct
of the test, classification of therapeutic responses, and identi-
fication of pitfalls with the test.
Some standardized in vivo tests impose an unnecessarily
stringent limit on parasite densities as an enrollment criterion.
This creates a potentially powerful selection bias when one
attempts to ascertain therapeutic responsiveness in communi-
ties by arbitrarily eliminating what is likely to be the median
parasite density in the community. Investigators should qualify
any subject having a microscopically proven diagnosis of P.
518 BAIRD CLIN. MICROBIOL. REV.
 
vivax asexual forms for enrollment, although hyperparasitemia
(not formally defined, but a value of 100,000 parasites/l has
been generally applied) should prompt intravenous quinine
therapy and thus disqualify the patient as a study subject. Prior
antimalarial therapy should not disqualify a potential subject,
as this tends to be the rule in areas of endemicity. Excluding
such subjects may also introduce selection bias in the estimate
of community failure rates.
Administration of therapy must exclude a primaquine ad-
junct until after day 28 because primaquine itself effectively
clears blood-stage parasites. The inclusion of primaquine at
the start of the test may therefore mask chloroquine-resistant
infections and cause an underestimation of the risk of thera-
peutic failure with chloroquine (14). Chloroquine therapy
should be directly observed by the research or clinical team or
by a responsible family member. The subject should be mon-
itored with blood film examinations by a clinically responsible
and practical schedule to day 28.
A subject with an asexual parasitemia level that either in-
creases or remains stable (25% of day 0 parasitemia) to day
2 should be given alternative therapy and provisionally classi-
fied as a direct treatment failure. A subject having an asexual
parasitemia of any level persisting to day 7 should be given
alternative therapy and provisionally classified as an early
treatment failure. For an asexual parasitemia that becomes
undetectable but reappears at any time between days 7 and 28,
the subject should be given alternative therapy and provision-
ally classified as a recurrence treatment failure. Subjects having
no recurrent parasitemia up to day 28 should be classified as
having had an infection that was sensitive to chloroquine.
Direct and early treatment failures may be definitively clas-
sified with a demonstration of adequately absorbed, fully com-
pliant therapy. This may be done by a direct observation of all
doses or by measuring CQDCQ levels after the last dose
(500 ng/ml whole blood is considered to be adequate). The
definitive classification of resistant phenotypes among recur-
rence failures must await a measurement of CQDCQ in
whole blood at the time of recurrent parasitemia. When
CQDCQ levels for any recurrence are below 100 ng/ml, the
infection must be classified as being ambiguous with respect to
sensitivity to chloroquine. The subject is considered to be a loss
to follow-up when later calculating the risk of therapeutic
failure in the community. When CQDCQ levels exceed 100
ng/ml, the parasite in that subject may be classified as being
resistant without regard to which day the parasite appeared.
Individual classifications of direct, early, or recurrent treat-
ment failures provide a generally useful empirical sketch of the
relative level of resistance in the community. This approach
also permits assigning relative levels of resistance to individual
parasite isolates. However, the best quantitative approach to
the characterization of measuring the adequacy of chloroquine
against vivax malaria in communities is the calculation of the
cumulative incidence of therapeutic failure across weekly in-
tervals using the life table method (14). The life table method
manages the probabilistic impact of losses to follow-up due to
the inability to find the subject, intercurrent parasitemia by
another species, or reappearance of vivax malaria with a value
of 100 ng/ml (almost all of which invariably occur). The
interval-specific cumulative incidence (or risk) of therapeutic
failure constitutes the basis for the data points shown in Fig. 4,
and Table 4 demonstrates the calculation of cumulative inci-
dence by the life table method. If the timing of recurrence
correlates with the degree of resistance (in correspondence
with levels of drug penetrated), a plot of 7-, 14-, 21-, and 28-day
cumulative incidences should intuitively reveal such distribu-
tions in any community surveyed.
The classification of parasite isolates as being sensitive or
resistant to chloroquine requires caution, especially when
these phenotypes are subsequently applied to studies of ge-
netic characteristics possibly linked to drug resistance. Para-
sites appearing on day 0 and failing to reappear within 28 days
may be confidently classified as being sensitive. The same may
be said of direct and early treatment failures. However, given
the ambiguities inherent with recurrent parasitemia during the
28-day test, the drug resistance phenotype of parasites col-
lected on day 0 remains uncertain. The parasites on day 0 that
are ultimately cleared may have been exquisitely sensitive to
chloroquine, and the parasites that later appeared during the
FIG. 4. Plot of the cumulative incidence of recurrent parasitemia
after chloroquine therapy of vivax malaria in western Indonesian
Borneo (167) and eastern Indonesian New Guinea (11).
TABLE 4. Life table estimation of cumulative incidence (risk) of
recurrent parasitemia after chloroquine therapy of vivax malariaa
Day
No. of subjects
remaining at
risk
No. of cases of
therapeutic
failure
No. of subjects
withdrawn for
any reason
Interval
riskb
Cumulative
riskc
0 34 0 0 0 0
2 34 2 1 0.0597 0.0597
4 31 0 0 0 0.0597
7 31 3 1 0.0984 0.1522
11 27 5 2 0.1923 0.3152
14 20 4 0 0.2000 0.4522
18 16 2 0 0.1250 0.5207
21 14 0 1 0 0.5207
28 13 3 2 0.2500 0.6405
a Reprinted from reference 15 with permission of the publisher.
b Interval risk was calculated as follows: i  N  (w/2)1, where N is the
number of subjects remaining at risk, i is the number of cases of therapeutic
failure, and w is the number of subjects withdrawn for any reason.
c The cumulative incidence of therapeutic failure (CRn) was calculated as
follows: CRn  1  (1  IRn) 	 (1  CFn  1), where IR is interval risk, n is
the day of the test, and n  1 is the prior interval. To calculate the CR for day
11, first estimate the interval risk as follows: 527 (2/2)1 0.1923 and, finally,
1  (1  0.1923) 	 (1  0.1522)  0.3152. Thus, the 11-day cumulative
incidence (or risk) of therapeutic failure was 31.5%.
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test could represent a relapse or reinfection by a chloroquine-
resistant strain. Therefore, only the parasites appearing on the
day of recurrence may be unambiguously classified as being
resistant to chloroquine.
The most important limitation of this in vivo test for chlo-
roquine is its practical irrelevance to any other drug. The
conduct and interpretation of the test rest on the highly specific
foundation of chloroquine excretion rates and minimally effec-
tive concentration in blood. Any other drug would impose
fundamentally different rules of logic necessarily supported by
a detailed knowledge of pharmacokinetics and parasite sensi-
tivities to the drug. Another obvious limitation of the in vivo
test is the need to have patients at all and then to be burdened
with monitoring them for 4 weeks. Also, the requirement for
measuring drug levels in blood severely limits the number of
clinics or laboratories that can do reliable testing (employing
rigorous high-pressure liquid chromatography of drug/metab-
olite extracted from volumetric blood dried onto filter paper).
Finally, confounding by natural immunity may be an important
limitation, especially in regions of high endemicity.
Ex vivo assay systems. The term ex vivo distinguishes sys-
tems using parasites removed from a subject and studied over
a limited period of time from the in vitro systems that use
preserved or continuously maintained parasites that may be
studied indefinitely in those systems. Limited successes have
been achieved with attempts to establish P. vivax in in vitro
systems. To date, there is no practical means of doing so. In
contrast, a variety of ex vivo techniques have been developed
for the direct observation of P. vivax in simplified laboratory
systems. Most of these techniques involve evaluating the in-
hibitory effect of blood schizontocides on live P. vivax asexual
blood stages (43, 84, 217). Relative objectivity represents the
principal advantage of ex vivo assays of drug sensitivity. In the
ideal system, parasites attempt growth in the absence of po-
tentially powerful confounding effects like host immunity, com-
pliance to prescribed therapy, absorption of drug, and the
above-discussed ambiguities regarding the origin of recurrent
parasitemia. Moreover, as described below, ex vivo systems
provide vital information on mechanisms of drug activity
against parasites and allow an exploration of the genetic bases
of drug-resistant phenotypes.
A detailed consideration of all of the published work in this
field exceeds the limits of this review. The focus here will be on
recent work from Thailand, Indonesia, and Myanmar high-
lighting two distinct approaches to the problem of gauging
parasite sensitivity to antimalarials.
Druilhe and colleagues (69) examined 17 isolates from an
area in southern Myanmar having documented resistance to
chloroquine in P. vivax with a cohort of subjects taking chlo-
roquine prophylaxis. Those researchers employed antiparasite
lactate dehydrogenase monoclonal antibodies to capture the
enzyme for detection by enzyme-linked immunosorbent assay,
with optical density output representing a measure of protein
synthesis. They employed a 50% inhibitory concentration cut-
off for the sensitivity of 100 nM chloroquine described by
others working with presumably chloroquine-sensitive P. vivax
isolates from Thailand (59, 218) and found 2 of the 17 isolates
to be resistant in their system. The primary advantage of the
lactate dehydrogenase capture system may be the objective
readout of optical density in an enzyme-linked immunosorbent
assay platform and its apparently superior sensitivity relative to
that of [3H]hypoxanthine incorporation (measuring DNA syn-
thesis) or microscopic examination.
Recent work from a research group of Thai, Indonesian,
Australian, and British collaborators dissected the key deter-
minants of ex vivo assay systems for P. vivax (189, 202). These
investigators derived a 50% inhibitory concentration threshold
for sensitivity based upon the known level of clinical resistance
of 65% at their study site (Timika, Papua, Indonesia). In other
words, they drew the ex vivo threshold where it classified 65%
of isolates as being resistant: 220 nM chloroquine. The basis
for the distinction between this estimate and the 100 nM value
described by Congpuong et al. (59) may lie in subsequent
findings regarding the developmental stage specificity of chlo-
roquine in P. vivax. Sharrock et al. (202) and Russell et al.
(189) identified important determinants of ex vivo responsive-
ness that would have been missed in more-automated systems.
They found P. vivax late trophozoites to be insensitive to chlo-
roquine, in sharp contrast with P. falciparum, and this key
discovery profoundly impacts the rationale and interpretation
of ex vivo assessments.
Parasitemia of P. vivax in patients often presents with most
stages of asexual development detectable in smears of periph-
eral blood. On the other hand, peripheral blood collected from
patients with P. falciparum usually contains parasitemias only
at the early trophozoite (ring) stage of development; more-
mature asexual forms tend to sequester in the deep vascula-
ture. In working with P. vivax ex vivo, the specificity of chlo-
roquine against early trophozoites emerges as a potentially
powerful confounding factor. If chloroquine fails to attack
more-mature trophozoites, their relative contribution to the
population going into the ex vivo well will obviously impact
maturation end points. A relatively mature parasitemia would
appear to be, perhaps falsely, highly resistant to chloroquine.
Apart from the practical importance of this finding, it also
sharply highlights the conspicuous lack of even the most fun-
damental understanding of how chloroquine kills P. vivax. We
have not known the stage of parasite targeted by chloroquine,
much less its mechanism of activity. The finding of chloro-
quine-insensitive trophozoites in P. vivax suggests a mechanism
of activity wholly distinct from that implicated for P. falciparum
and linked to hemozoin synthesis (detoxification of digested
hemoglobin heme by chemical aggregation). Visible clumps of
hemozoin appear in young ring forms of P. falciparum, but in
P. vivax, these do not appear until the blood-stage schizont
reaches maturity. Thus, late hemozoin synthesis in P. vivax
appears to be unaffected by chloroquine.
The development of a standardized ex vivo assay for assess-
ing the therapeutic susceptibility of discrete isolates of P. vivax
should be a very high research priority. That effort must iden-
tify a means of analytically coping with the apparently inherent
late-trophozoite-stage insensitivity to chloroquine and perhaps
other drugs. Assumptions of similar mechanisms of blood schi-
zontocidal activity between P. falciparum and P. vivax should
be abandoned, and work should be focused upon elucidating
mechanisms of activity in the treatment of vivax malaria.
Animal models. Nonhuman primate models have long pro-
vided access to well-characterized strains of P. vivax to labora-
tories located far from zones of endemicity. Much of the work
focused upon preclinical drug and vaccine studies, especially
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for P. falciparum. Similar work occurred with P. vivax, and the
availability of animal models served the additional role of
addressing relatively simple standing questions created by the
inability to maintain the parasite under continuous in vitro
cultivation. One of those was the question of resistance to
chloroquine in P. vivax. In the absence of an in vitro assay and
of molecular evidence of resistance, could the relatively am-
biguous clinical failures observed for patients in areas of en-
demicity be confirmed by more-objective means?
P. vivax readily infects a number of other primates including
chimpanzee, gibbon, owl monkey, squirrel monkey, spider
monkey, some tamarins, and white-faced monkey (51). The
owl and squirrel monkeys have emerged as the favored model
by virtue of availability and ease of care and infection (54).
Infections by chloroquine-sensitive strains of P. vivax have
been treated using these models, including the Chesson, Palo
Alto, and Achiote strains (58, 186, 194). This record of sensi-
tivity of strains isolated well before the onset of prevalent
resistance serves as a therapeutic benchmark against which
other strains may be classified as being susceptible or resistant
to chloroquine.
This was the approach taken by Collins et al. (55) in assess-
ing the I/CDC strain of P. vivax from Sumatra, Indonesia.
Recrudescence of this strain occurred in all four Aotus and five
of six Saimiri monkeys challenged and treated with regimens of
chloroquine that were effective against the Chesson strain of P.
vivax in the same animal system. Collins et al. (57) also char-
acterized the XIX/CDC strain of P. vivax from Indonesian New
Guinea in a similar system. They described a 30-mg dose (given
by gavage over 3 days) as being uniformly effective against
chloroquine-sensitive P. vivax isolates, but that standard dose
against the Indonesian XIX/CDC strain failed within 28 days in
9 of 11 monkeys. These studies provided independent corrob-
oration of resistance to chloroquine in P. vivax, a diagnosis that
had been made using an experimental in vivo testing format.
Mechanisms and Markers
The mechanism of chloroquine activity against blood stages
of P. vivax remains unknown. Most of what has been reported
for the subject defaults to the relatively vast experimental data
for P. falciparum, virtually all of it being derived from contin-
uous culture systems for that parasite. The search for molec-
ular markers of resistance in P. vivax thus naturally focuses
upon orthologs of incriminated mutant genes and loci in P.
falciparum, namely, P. vivax mdr1 (Pvmdr1) and Pvcrt-o. In P.
falciparum, sequence mutations and amplification of these
genes have each been linked to the resistance phenotype, and
these have also been investigated using P. vivax.
Nomura et al. (156) found no relationship between muta-
tions in Pvcrt-o and either chloroquine therapeutic phenotype
or accumulation of chloroquine in a novel surrogate protozoan
(Dictyostelium, an amoeboid slime mold) in vitro model. Sa et
al. (191) found no Pvmdr1 mutations that correlated with chlo-
roquine-resistant phenotypes. Sa et al. (192) nonetheless
showed that Pvcrt-o plays a role in chloroquine transport across
membranes in an experimental system using P. falciparum
transformed with that gene. Moreover, they applied an engi-
neered mutant of Pvcrt-o (threonine at position 76) in the
Dictyostelium system and demonstrated an impaired accumu-
lation of chloroquine relative to that of wild-type Pvcrt-o.
Suwanarusk et al. (212) identified Y976F mutations in
Pvmdr1 as being highly prevalent among relatively large num-
bers of isolates (128) from a site in Indonesian Papua known to
have a 65% risk of clinical resistance to chloroquine in vivax
malaria compared to 69 Thai isolates, where almost uniform
sensitivity to chloroquine prevails. Ninety-six percent of Indo-
nesian isolates had this mutation, compared to 25% of Thai
isolates. Those found amplified Pvmdr1 to be more common in
Thailand (21%) than Indonesia (0%) but not apparently linked
to drug resistance. However, Suwanarusk et al. (213) also ex-
amined 71 and 114 P. vivax isolates from Thailand and Indo-
nesia, respectively, finding increased copy numbers of Pvmdr1
in 21% of Thai isolates and none among the Indonesian iso-
lates. Those authors also found relatively high inhibitory con-
centrations of mefloquine, artesunate, and lumefantrine in ex
vivo tests of Thai parasites. Taken together, their findings
suggest an inverse relationship between the copy number of
this gene and resistance to chloroquine and susceptibility to
mefloquine, as occurs with P. falciparum.
Imwong et al. (110) examined Thai P. vivax isolates for
Pvmdr1 amplification by comparing 66 isolates from the west-
ern Thai border to 149 isolates collected elsewhere in South-
east Asia. Those authors suggested a relationship between
Pvmdr1 and the clinical use of mefloquine. Among the 16
isolates checked for the Y976F mutation in Pvmdr1, 1/11 and
3/5 isolates from Thailand and Myanmar, respectively, had this
mutation.
When Fernandez-Becerra et al. (78) compared a patient
with severe vivax malaria (responsive to quinine intravenous
therapy) to another patient with uncomplicated malaria, they
found amplified copy numbers of both Pvmdr1 and Pvcrt-o in
the former patient. No studies have systematically evaluated
these genes in sufficiently large series of patients with nonse-
vere versus severe disease.
No firm evidence yet links amplifications or polymorphisms
in any gene of P. vivax to clinical resistance. The search to date
has been limited to genes suspected in P. falciparum drug
resistance despite early evidence suggesting distinct mecha-
nisms at work between these species.
Distribution
Reliable surveys of resistance ascertained CQDCQ levels
of100 ng/ml whole blood on the day of recurrence. In the ab-
sence of recurrence, no drug levels are needed to make the
diagnosis of sensitivity to chloroquine. Figure 5 represents the
application of this standard to systematic surveys of chloro-
quine resistance in vivax malaria. The surveys, reflecting more
than a decade of observations, reveal the paucity of data.
Accepting that the data provide at best a rough sketch of risk
by geographic zone, it seems clear that eastern Indonesia rep-
resents the most advanced resistance problem, with a 50%
probability of therapeutic success apparently being the norm
(12, 14, 15, 180, 210, 211). Few data have come from nearby
Papua New Guinea (87), and even less data have come from
further eastward to Vanuatu. Across the western Indonesian
archipelago to the Malay Peninsula, therapeutic success rates
have consistently ranged between 75% and 90% (80, 81, 82, 83,
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220); however, a recent study in southern Sumatra found
50% treatment success (I. Sutanto, University of Indonesia,
unpublished data). Recent reports from southern Myanmar
and Vietnam also showed successful treatment rates within the
range of 75% to 90% (95, 167, 219). A number of reliable
studies involving large numbers of patients in both Thailand
(59, 125, 136, 217, 229) and India have shown almost uniform
susceptibility to chloroquine in vivax malaria (154, 226), al-
though very recent work from the Gujarat State in western
India found a 91% success rate among 65 evaluated patients
(209). Studies in Pakistan, Afghanistan, and Azerbaijan have
shown little or no evidence of resistance (121, 134, 227). Re-
ports from Turkey showed 85% to 90% susceptibility (129), but
a more recent survey from the southeastern sector showed only
78% susceptibility (130). Systematic surveys in South America
showed evidence ranging from complete susceptibility to a very
low risk of resistance (5%) (38, 188), but one survey of just
27 patients found 89% susceptibility (207). A relatively recent
report from Manaus, Brazil, found 10% of 109 subjects eval-
uated to have had apparently adequate levels of chloroquine in
plasma at the time of recurrent parasitemia within 28 days
(66).
In summary, the Indonesian archipelago, especially in the
east, carries the highest risks of resistance of P. vivax to chlo-
roquine. Most recent data also suggest an increasing risk on
the nearby Malay Peninsula, including Myanmar, and eastward
to southern Vietnam. With the notable exceptions of studies in
southeastern Turkey, a single study in India, and one in Brazil,
risk elsewhere currently appears to be low.
RESISTANCE TO PRIMAQUINE
Definition
Arnold et al. (10) induced complete resistance to the highest
tolerated doses of primaquine by asexual blood stages of the P.
vivax Marvel strain (derived from the Chesson strain). Those
researchers initially administered suboptimal daily doses (22.5
mg), and through 36 sequential passages, they reached daily
doses of primaquine as high as 140 mg (for adult subjects,
which is well beyond normal therapeutic dosing), with no dis-
cernible impact upon asexual parasitemia. That report dealt
only with blood stages of P. vivax, against which primaquine
normally has good efficacy at therapeutic doses (174). How-
ever, primaquine is very rarely applied as a blood schizontocide
against P. vivax, and it has very poor activity against asexual
blood stages of P. falciparum (11). Resistance to primaquine in
asexual blood stages has little therapeutic relevance, and no
linkage is known for drug resistance in blood and liver stages.
This review deals exclusively with the issue of resistance to
primaquine in the liver stages.
Collins and Jeffery (56) pointed out the bias for both blood
schizontocides and P. falciparum in most conventional defini-
tions of resistance to antimalarials. A working definition of
resistance to primaquine had not been put forth, much less
validated. They advocated the application of the term resis-
tance within relatively strict limits, namely, direct evidence of
therapeutic failure of a given dose known to be effective within
a given geographic locale or for a given strain of parasite. They
pointed out that the “… characteristic requirement for higher
doses of primaquine for curative effect in vivax malarias of the
South Pacific and Southeast Asia is one of long standing, not
one that has emerged recently.” Indeed, tropical Southeast
Asian strains have shown consistently poor therapeutic re-
sponses to primaquine as far back as 1944, when the Chesson
strain of P. vivax infected an American soldier in New Guinea
(Chesson was the name of the soldier) (74) and was used
extensively in the subsequent development of primaquine
against relapse (239).
The wartime genesis of the Chesson strain and its well-
known refractoriness to primaquine merit examination in dis-
cussions of terms and their meaning in a biological sense. The
term tolerant implies a permanent, long-standing, or even in-
herent ability to survive ordinarily effective and practical reg-
imens of a given therapy. The fact that primaquine had not
been developed in 1944 and the Chesson strain showed poor
efficacy with standard primaquine therapy (15 mg daily for 14
FIG. 5. Distribution of confirmed resistance to chloroquine in P. vivax.
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days) relative to that with most temperate strains suggests an
inborn tolerance of primaquine. However, the Chesson strain
may have acquired resistance to 8-aminoquinolines like prima-
quine through selection pressures applied by therapeutic prac-
tices. From 1942 to 1945, New Guinea hosted many tens of
thousands of Japanese, American, Australian, New Zealand,
and Fijian troops engaged in combat for military control of the
island. The strategic importance of malaria in that struggle was
detailed previously (25, 68, 113).
Atebrine (also called quinocide or mepacrine) is a now ob-
solete 9-aminoacridine invented by the Germans in the 1930s
as a synthetic replacement for quinine. The fall of Java in the
Dutch East Indies to Japanese forces in early 1942 resulted in
the loss of 95% of the world’s quinine supply to Allied nations,
and atebrine very suddenly found wide application. Its en-
forced use among both troops and indigenous people residing
close to encampments has been documented (25, 68, 113).
Atebrine was new to most doctors in 1942. According to Joy
(113), “there was no published doctrine for its use, nor any
information on side effects. The medical officers thus invented
their own programs. These ranged from daily use of 0.1 gme to
twice a week administration of 0.2 gmes, to 0.05 gmes for 5
days with 2 days of ‘rest.’ ” The production and distribution of
atebrine to forces, especially those engaged in the Southwest
Pacific theater of war in 1942, had been a strategic urgency. As
Joy (113) pointed out, by the standards of today, its clinical
application could be characterized as experimental and reck-
less. There could be fewer better formulas for selecting para-
sites that are resistant to the drug and, perhaps, structurally
related drugs as well.
The German chemists that synthesized atebrine had used
the chemical structure of pamaquine as their starting point
and, after examining over 12,000 compounds using bird mod-
els, found that substituting the quinoline ring with acridine
provided the best therapeutic index (Fig. 6). These structurally
related compounds may share some characteristics of resis-
tance, but a highly atebrine-resistant line of Plasmodium
berghei (M line) was cross-resistant to quinine and chloroquine
but not primaquine (against blood stages) (163).
Bennett (25) shed new light on Allied antimalarial practices
on New Guinea that bear more directly upon resistance to
primaquine. That author described the widespread use of the
original 8-aminoquinoline, pamaquine (plasmoquin) (Fig. 6),
among Allied troops and, especially by American forces,
among the many thousands of local inhabitants which they
encountered during the progress of the war. The applied doses
(20 mg daily for 5 day) were apparently intended to provide
gametocytocidal activity and curb transmission. According
to military historian Alan Hawk (http://ajrp.awm.gov.au/ajrp
/remember.nsf/pages/NT000022CA?openDocument), Japa-
nese troops in New Guinea also used pamaquine (plasmochin)
both as prophylaxis against infection (in a single weekly dose)
and as a supplement to quinine therapy. Pamaquine preven-
tion and treatment trials were among the studies undertaken
by Fairley’s Australian Army Medical Research Unit at Cairns
during the war (77, 214). Their focus on strategically urgent
drugs lends further credence to the apparent importance and
use of pamaquine for troops in the field at that time.
A circular published by the U.S. Surgeon General in 1943
(158) carried recommendations for therapeutic practice with
pamaquine that acknowledged the phenomenon of the en-
hancement of pamaquine toxicity by atebrine. The Allies, in
effect, surrendered to relapse by applying regimens of pama-
quine aimed only at the elimination of gametocytes and reduc-
ing the risk of further transmission.
Atebrine and pamaquine were widely employed by military
forces at war in New Guinea beginning in 1942 and persisting
through 1945. The widespread application of often subthera-
peutic regimens of these two drugs that were structurally re-
lated to primaquine against a pervasive malaria threat may
account for the relatively poor responsiveness of the Chesson
strain of P. vivax to antirelapse therapy with primaquine. His-
torical accounts of the conduct of the war in the Pacific, espe-
cially in New Guinea, support the supposition of a pervasive
and persisting selection pressure favoring the emergence of P.
vivax that is resistant to 8-aminoquinolines. Indeed, the Ches-
son strain proved to be far more resistant to pamaquine than to
primaquine relative to the normal level of activity of each drug
against other strains; whereas daily adult doses of 15 mg and 27
mg (for 14 days) of primaquine and pamaquine, respectively,
prevented relapse against other strains of vivax malaria, doses
of 30 mg primaquine and 90 mg pamaquine were required to
achieve the same effect against the Chesson strain (5, 62).
Thus, the Chesson strain of P. vivax may be considered to be
pamaquine resistant and very likely cross-resistant to prima-
quine.
Collins and Jeffery (56) expressed unease with the term
“resistant,” apparently preferring either primaquine tolerant
or primaquine refractory. They reserved use of the term for
demonstrations of eroded efficacy within an area. Baseline data
for sensitivity to primaquine prior to 1944 do not exist, and
classification of the Chesson strain as being resistant to prima-
quine is thus eluded within their framework. Indeed, even
today, the availability of baseline data documenting bench-
mark sensitivity anywhere is exceedingly rare. This constitutes
the primary problem with applying the framework for defining
resistance as put forth by Collins and Jeffery (56): the almost
universal absence of benchmarks against which an erosion of
efficacy may be measured. The task of gauging the therapeutic
FIG. 6. Chemical structures of chloroquine, pamaquine (plasmo-
quin), mepacrine (atabrine), and primaquine.
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utility of primaquine seems to be unmanageable, and the root
of the problem lies in the interpretation of Chesson strain
responsiveness to primaquine as being reflective of an inherent
tolerance of the drug that may naturally vary with geography
and strain.
The above-described detail afforded by the genesis of the
Chesson strain provides the basis of a differing view. The army
of Sergeant Chesson moved with many thousands of his fellow
soldiers against many thousands of Japanese soldiers, each
surrounded by thousands of indigenous Papuans. Malaria at-
tack rates were extraordinarily high: Australian forces at Milne
Bay in December 1942 suffered 4,200 malaria cases/1,000 per-
son-years (25). Atebrine and pamaquine were the primary
drugs applied against malaria. The Chesson strain of P. vivax
should not be considered to be representative of a naturally
occurring heterogeneity of sensitivity to primaquine. The evi-
dence of circumstance instead points to a unique milieu of
intense drug use and parasite exposure to those drugs, allowing
the emergence of strains that were resistant to those drugs.
Defining resistance to primaquine requires setting a baseline
sensitivity of Plasmodium vivax to the drug. The originally
recommended standard therapy, a 15-mg base adult dose (or
0.25 mg/kg) once daily for 14 days, stands as an obvious can-
didate benchmark. This regimen provided nearly complete ef-
ficacy against strains from India, Vietnam, South Korea, and
both temperate and tropical Americas (5, 49, 85, 90, 114, 148,
231). Even lower doses (10 mg/day for 14 days or 15 mg/day for
7 days) provided good efficacy (67, 221). The documented
sensitivity of all strains of P. vivax, which was evaluated to be 15
mg daily for 14 days (adult dose), except for a single strain
isolated from a soldier engaged in combat operations in New
Guinea in 1944 (74), points to the use of that standard regimen
as a benchmark of primaquine sensitivity for the species. This
approach provides an enabling framework for gauging the en-
croachment of resistance to primaquine in P. vivax.
Diagnosis
No means for the diagnosis of resistance to primaquine by
liver stages of vivax malaria has been standardized or validated.
What follows represents a practical means of coping with the
many nuanced ambiguities of therapeutic responses to this
drug. The most important issues to address include reinfection,
recrudescence (companion blood schizontocide), and compli-
ance to prescribed therapy.
Confounding by reinfection. Evaluation of primaquine effi-
cacy must allow for a relatively long-term follow-up of subjects
for the detection of late relapse. This may be especially true in
temperate zones, where late relapse is the rule, but it is also
true in the tropics, where both early and late relapses occur,
and these may have distinct responses to therapy (1). More-
over, more than half of subjects experienced therapeutic fail-
ure after day 28 when Alving et al. (4) evaluated 18 pamaquine
analogs against relapse. This imposes a rather strict and con-
straining requirement for ensuring a very low probability of
reinfection during the follow-up period. As discussed above,
the molecular tools for classifying recurrent P. vivax infections
as recrudescences, reinfections, or true relapses do not yet
exist, and this limits meaningful evaluations to specific popu-
lations, i.e., infected travelers repatriated to nonendemic areas.
An alternative approach for coping with reinfection may be
simply to measure the incidence of new infections and account
for this in estimating primaquine efficacy. In a single study
population randomized to three separate treatment groups,
one may estimate the efficacy of any given primaquine regimen
by measuring recurrences in a group given a regimen of pri-
maquine that is certain to be effective and among those given
a placebo for primaquine. This approach may account for
confounding by reinfection, but statistical constraints probably
limit practicality where reinfection probabilities exceed 20%
per year.
Confounding by recrudescence. A potential study subject
will be diagnosed with microscopically patent parasitemia with
P. vivax. PCR diagnostics may complement that diagnosis but
not supplant it, as no means of PCR diagnosis has been cred-
ibly validated with reliable estimates of specificity and sensi-
tivity. There is no analytically valid basis for setting limits on
the density of parasitemia in these subjects. Reliable evidence
of parasitemia serves as simply an indicator of a likely infection
of liver with hypnozoites. However, some patients may be
disqualified on the basis of severe disease or an inability to
adhere to oral primaquine administration.
The diagnosis comes with the obligation to treat acute dis-
ease, and a blood schizontocide must be promptly applied. The
selection of that drug bears directly upon an evaluation of the
efficacy of primaquine against liver stages. The use of chloro-
quine as a blood schizontocide is not recommended. Con-
firmed resistance to chloroquine by P. vivax leaves open the
likelihood of recrudescence as a possible source of recurrent
parasitemia. Nonetheless, primaquine may require chloro-
quine to achieve killing of hypnozoites, and the drug must be
administered as a companion tissue schizontocide. The certain
killing of blood stages must be accomplished with a third drug,
and its selection and administration must be carefully consid-
ered with respect to yielding findings that may be reliably
analyzed.
The blood schizontocide must be known to be completely
efficacious against blood stages, and it must be rapidly excreted
so as not to interfere with the combination of primaquine and
chloroquine against liver stages. The drug must be adminis-
tered upon diagnosis and almost completely eliminated before
beginning the administration of primaquine and chloroquine.
Good candidates for a blood schizontocide include quinine or
any of the artemisinins. Each of these has evidence of good
efficacy against blood stages of P. vivax and is rapidly excreted.
Compliance to therapy. The administration of 15 or 30 mg
primaquine daily for 14 days (depending upon local practice
and the objective of the survey) should commence on about
day 7 after starting treatment of the blood-stage infection and
should be given concurrently with a standard dose of chloro-
quine (10 mg/kg starting with the first dose of primaquine,
followed by 10 mg/kg with the second dose and 5 mg/kg with
the third dose). A subject free of risk of reinfection and given
these therapies under some form of supervision is thus posi-
tioned for follow-up yielding meaningful insights with respect
to the therapeutic response of liver stages of P. vivax to pri-
maquine (and chloroquine).
Confounding by chloroquine in blood. The application of
chloroquine and its approximately 35 days of effective levels
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against P. vivax in blood will suppress the earliest relapses of
chloroquine-sensitive P. vivax strains. This may bias the eval-
uation toward an overestimation of sensitivity to primaquine.
However, the early-relapsing tropical strains of P. vivax also
show a propensity for multiple relapses, and the emergence of
primaquine-resistant hypnozoites during a year of follow-up
seems highly likely. An alternative approach may be to apply
quinine as both the companion tissue schizontocide and blood
schizontocide. Quinine also potentiates the activity of prima-
quine against liver stages (6, 195).
Analysis. Follow-up duration and the interpretation of re-
current parasitemia constitute the diagnosis of resistance to
primaquine. Provided that the eradication of asexual blood
stages was achieved and reinfection has been reliably excluded
(or measured), recurrent parasitemia may be assigned to emer-
gence from the liver and thus represent therapeutic failure of
the applied tissue schizontocide.
Almost all tropical P. vivax cases may be expected to
relapse within a month and several times over a prolonged
period (a year or more), whereas only about 20 to 40% of
temperate (or Indian) P. vivax cases relapse at all and tend
to do so only once between 6 and 12 months. The period of
follow-up should be adapted to local relapse patterns. More-
over, at least one study suggested distinct therapeutic re-
sponses to primaquine (and elubaquine) by hypnozoites
tending to relapse early versus late (1). The risk of relapse
appeared to be higher in the short term than in the long
term. Although the likelihood of confounding by recrudes-
cence of chloroquine-resistant asexual blood forms could
not be ruled out in that study, the finding bears consider-
ation in planning an analysis of primaquine resistance. Cer-
tainly, evaluations of tropical vivax malaria should include
efficacy end points at 30, 60, 120, 240, and 365 days, for
example, to capture such possible differences in therapeutic
responsivenesses of early compared to late hypnozoites.
The possibility exists that so-called early relapses caused by
tropical Asian P. vivax may not be relapses but simply slow-
developing primary tissue schizonts. This would very likely
impact the therapeutic responsiveness to any given drug ap-
plied, i.e., targeting true hypnozoites or not (Fig. 2). However,
the apparently strict 17-day pause between primary para-
sitemia and first recurrent parasitemia argues against that hy-
pothesis.
Mechanisms and Markers
No mechanism or marker of resistance of liver-stage P.
vivax to primaquine is known. Progress in this area likely
awaits the successful establishment of hypnozoites in human
hepatocyte cell lines in vitro, especially those allowing an
analysis of the parasite transcriptome at this stage. The
systematic collection of strains that are reliably phenotyped
as being sensitive or resistant to primaquine in clinical stud-
ies would bring considerable analytical leverage to the ex
vivo work. Genomic and proteomic studies comparing the
Chesson and Korean strains of P. vivax may yield insights
into the genetic determinants of relapse and, perhaps, sus-
ceptibility to primaquine.
Distribution
No studies have yet followed the guidelines for the diagnosis
of resistance to primaquine outlined above. Objective assess-
ments of the risk of therapeutic failure in any given region
remain elusive. Nonetheless, many reports of both case and
clinical studies provide a crude gauge of the geographic distri-
bution of risk.
The broad assertion that P. vivax strains from Southeast Asia
are less responsive to primaquine than strains from elsewhere
(39, 43, 123) rests largely upon evidence from clinical trials in
Thailand. Although Luxemburger et al. (137) found a 91%
efficacy of 15 mg daily for 14 days with 2 months of follow-up,
Walsh et al. (232) and Pukrittayakamee et al. (174) measured
efficacies of that regimen to be 69% and 42%, respectively.
Standard 14-day therapy of 15 mg daily failed more often than
either the 22.5- or 30-mg daily regimen (34, 174), and the
22.5-mg daily regimen failed more often than did the 30-mg
daily regimen (117). Likewise, a 30-mg daily dose works better
when given for 11 or 14 days than when given just 5, 7, or 9 days
(127). Vivax malaria acquired in Southeast Asia seems to re-
quire at least 30 mg daily for 14 days (or twice daily for 7 days)
(127) to prevent relapse. In Vietnam, 1 of 28 subjects had
recurrent parasitemia within 28 days after therapy with 22.5 mg
primaquine twice daily for 7 days (64). Earlier studies in Viet-
nam (114) showed 4% relapse rates among repatriated Amer-
ican soldiers given supervised therapy and monitored for a
year. Vivax malaria acquired in Southeast Asia very likely
requires 30 mg primaquine daily for 14 days to achieve good
efficacy against relapse.
The wide perception of New Guinea, the source of the
Chesson strain, as harboring primaquine-tolerant or -resistant
strains of P. vivax lacks direct substantiating data. No direct
measures of the efficacy of primaquine against relapse have
come from the island since the work with the Chesson strain
more than 50 years ago. However, two separate large studies
reported that travelers to New Guinea with vivax malaria who
were treated with standard primaquine therapy were 8 to 12
times more likely to suffer relapse after primaquine therapy
than patients who acquired their P. vivax infection anywhere
else (75, 112). Vivax malaria acquired on the island of New
Guinea indeed appears to be more prone to relapse after
primaquine therapy than vivax malaria acquired in other re-
gions. Effective therapy against relapse of vivax malaria ac-
quired on the island of New Guinea may require at least 30 mg
daily for 14 days, and administration of that dose for 21 days
(or more) may be prudent.
Data from the Korean Peninsula, India, Pakistan, and Af-
ghanistan also suggest that 30 mg daily for 14 days may be
required for good efficacy against relapse by P. vivax. Park and
Kang (162) measured only a 32% effectiveness of postexposure
presumptive therapy with the 15-mg daily (14-day) regimen for
tens of thousands of soldiers from the Republic of Korea. The
30-mg daily (14-day) regimen achieved 94% efficacy in the
northwestern frontier of Pakistan (135), whereas a supervised
regimen of 15 mg daily achieved only 48% efficacy in the first
3 months in the same region (133). Another study in the same
region recorded a 35% efficacy for that regimen (187). Spudick
et al. (208) detailed the case of an American soldier repatri-
ated from duties in Iraq and Afghanistan with three successive
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episodes of vivax malaria (two episodes requiring hospitaliza-
tion and prolonged mechanical ventilation) despite adminis-
tration of 30 mg daily for 14 days for each episode. In India,
Rajgor et al. (178) found only 50% efficacy for the 15-mg daily
regimen (14 days), but Gogtay et al. (90) found no relapses
among 242 subjects thus treated in Mumbai (versus 12% re-
lapsing without primaquine).
Risk of reinfection may confound these studies from India,
Pakistan, and Afghanistan with long-term follow-up (9 to 12
months). An equal force of reinfection among placebo- and
primaquine-treated groups would have the effect of diminish-
ing estimates of efficacy in proportion to incident new infec-
tions. For example, if 20 true relapses occurred in the placebo
group of 100 subjects and just 1 occurred in the primaquine
treatment group of 100 subjects, the estimate of efficacy would
be 95%. If during the course of 6 months of follow-up, each of
the groups of 100 subjects experienced 15 new infections, the
realized estimate of efficacy would be 54%. This problem can
be addressed with a third treatment arm measuring the force of
new infections (see above). Data from one study in Pakistan
tend to support this impact in the given estimates of efficacy
from that region. When Leslie et al. (135) examined the inter-
val-specific efficacy of primaquine, the estimates were 48%,
73%, and 92% at intervals of 0 to 3 months, 4 to 6 months, and
7 to 9 months, respectively. The latter intervals would have
been less likely to have reinfections due to the sharp season-
ality of transmission at that study site. The available data from
this region suggest a high risk of failure with the 15-mg daily
regimen versus the consistently good efficacy of the 30-mg daily
regimen.
Vivax malaria occurs in relative abundance in eastern Africa
including Madagascar. Schwartz and Sidi (199) reported 50%
attack rates among Israeli travelers to Ethiopia despite sup-
pressive prophylaxis. A survey of 11,504 Ethiopians revealed a
1.6% prevalence of microscopically patent parasitemia caused
by P. vivax (76). Among 4,801 cases of vivax malaria imported
into Europe between 1999 and 2003, 16% of cases came from
eastern and southern Africa (152). Surprisingly, 18% of those
cases came from the rest of the continent despite an extremely
low prevalence of detectable parasitemia in that region (63).
Virtually nothing is known of the responsiveness of African P.
vivax strains to primaquine. Smoak et al. (204) described 60
American soldiers developing vivax malaria after repatriation
from Somalia and being treated with unsupervised standard
primaquine therapy: 26 soldiers (43%) relapsed.
The available data on primaquine efficacy from South Amer-
ica point to a similarly poor performance of the 15-mg stan-
dard regimen. Duarte et al. (70) managed 50 patients with
vivax malaria through a supervised 15-mg daily regimen (14
days) and 6 months of follow-up in an area without risk of
reinfection: 7 of those patients experienced relapse. It was not
possible to calculate efficacy without a placebo control, but the
14% relapse rate among patients given supervised therapy
strongly suggests an inadequacy of the regimen. Alvarez et al.
(3) monitored 210 subjects with vivax malaria for 6 months
after therapy with total primaquine doses of 45, 105, and 210
mg in a region of Colombia where malaria is endemic. Relapse
occurred in 45%, 37%, and 18% of these subjects, respectively.
Setting aside the issue of confounding by reinfection (as dis-
cussed above) and applying the 45-mg treatment group as
being representative of a placebo control group yielded an
estimate of efficacy of 60%. Villalobos-Salcedo et al. (230)
compared a standard 14-day regimen of 15 mg primaquine
with a 5-day regimen among 61 adults with vivax malaria in
Brazil monitored for 60 days after treatment. Again setting
aside confounding by reinfection and supplanting a placebo
control with the 5-day treatment group yielded an estimate of
efficacy of 76%. Arias and Corredor (9) detailed 11 cases of
relapse following standard primaquine therapy in Colombia.
Gascon et al. (86) described two cases of primaquine failure
from Guatemala who were treated in Spain. Finally, Nayar et
al. (155) described the primaquine-resistant Brazil I/CDC
strain of P. vivax coming from a traveler infected in Brazil who
failed three separate courses of 15 mg daily for 14 days but
finally succeeded with that regimen after it was administered
over 28 days. Vivax malaria from South America appears to
respond poorly to the 15-mg (14-day) regimen, and the 30-mg
regimen should be applied.
RESISTANCE TO ANTIFOLATES
Malariologists have long known P. vivax to be intrinsically
capable of developing resistance to pyrimethamine relatively
quickly (104). The most widely applied antimalarial in this class
of drugs was the fixed combination of SP, targeting parasite
dihydropteroate synthase and dihydrofolate reductase (DHFR),
respectively. Hawkins and colleagues (101) constructed a his-
tory suggesting that the early perception of poor efficacy
against asexual blood stages may have been a product of con-
fusion with the failure of either drug to prevent relapse in P.
vivax. Those authors pointed to an exceptional study of the
effect of pyrimethamine on the Chesson strain of P. vivax
conducted by Coatney et al. (48) that characterized the activity
of pyrimethamine against this parasite as being superior.
Hawkins et al. (101) contrasted that with data from a report by
Young and Burgess (241) emphasizing the intrinsic suscepti-
bility to induced resistance to pyrimethamine. Those investi-
gators also linked the clinical failure of SP against P. vivax to
the accumulation of multiple mutations in DHFR, with wild-
type DHFR isolates showing in vivo sensitivity to SP therapy
(97, 109), along with in vitro evidence of a similar process in
transfected Saccharomyces cerevisiae systems (97, 98).
The picture that emerges tends to undermine the perception
of P. vivax as being intrinsically not responsive to SP therapy.
The broad deployment of SP against P. falciparum would have
exerted incidental selection pressure for DHFR/dihydrop-
teroate synthase mutations in P. vivax. Available evidence
points to the acquisition of a sufficient number of mutations in
DHFR to create a high probability of therapeutic failure
against P. vivax. The likely persistence of some wild-type
DHFRs among P. vivax isolates, however, does not necessarily
argue for the deliberate application of SP against this infection.
The broad lack of technological capacity in areas of endemicity
would almost always preclude genetic screening prior to SP
therapy. The importance of the distinctions pointed out by
Hawkins et al. (101) instead lies in the realization that the
machinery of folate metabolism in P. vivax represents poten-
tially highly vulnerable targets of chemotherapy and merits
exploration in drug development.
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GAMETOCYTOCIDAL THERAPIES
The above-described presentation of chloroquine as being
an ideal antimalarial drug comes with an important caveat,
which is its failure to adversely affect the gametocytes of P.
falciparum, and it apparently even enhances the likelihood of
transmission, especially for chloroquine-resistant strains (35,
107). This biology may have had a direct role in the nearly
complete proliferation of chloroquine-resistant falciparum ma-
laria that occurred between 1945 and 1985.
The same biology is not true for P. vivax and may likewise at
least partially explain the relatively slow appearance and
spread of chloroquine-resistant P. vivax. Jeffery (111) provided
conclusive evidence that either standard oral or intramuscular
chloroquine therapy against the Chesson strain of P. vivax
caused an abrupt and complete halt to infectivity to Anopheles
quadrimaculatus mosquitoes among 20 gametocytemic human
subjects. Nonetheless, P. vivax, like most other plasmodia and
unlike P. falciparum, undergoes gametocytogenesis relatively
early during blood-stage development. P. vivax gametocytes
may appear in the bloodstream before the onset of symptoms
of acute malaria (30, 96) and perhaps provide the opportunity
for transmission before treatment of any kind is administered.
However, in a series of 152 neurosyphilis patients challenged
with the St. Elizabeth (North American) strain of P. vivax,
McKenzie et al. (144) found that fever preceded gameto-
cytemia by several days.
If the transmission of vivax malaria occurs in asymptomatic
(and untreated) hosts, the parasite will not directly experience
drug selection pressure, and drug sensitivity would likely pre-
vail. However, as demonstrated by the P. falciparum-chloro-
quine example, the application of a therapy that does not
eliminate infectious gametocytes may have long-term conse-
quences with severe public health impacts. Peters et al. (166)
used a rodent malaria system to demonstrate the ability of a
gametocytocide to protect the blood schizontocide from the
onset of resistance. The evaluation of new therapies for P.
vivax should consider the important issue of gametocytocidal
properties.
Butcher (35) reviewed various approaches to assessing ga-
metocytocidal activity and the available data up to 1997. That
author explained the technical basis for considering human
subjects infected and infectious to directly fed mosquitoes as
the ideal system for ascertaining gametocytocidal activity.
Studies by Jeffery (111) represent this ideal system. Klein and
colleagues (118) approached this ideal using P. vivax-infected
subjects given standard therapies but used membrane feeding
of mosquitoes. They showed chloroquine and primaquine com-
bined required at least 5 h to affect transmissibility. Ex vivo
and/or in vitro systems present pitfalls in interpretation but
may be ideally suited to the screening of relatively large num-
bers of experimental drugs in preclinical evaluations, as
Coleman et al. (53) demonstrated with seven compounds
against P. vivax. The same group (169) applied a similar system
to demonstrate the transmission-blocking activity of tafeno-
quine and artelinic acid (as metabolized in mice) against P.
vivax in Anopheles dirus mosquitoes.
Studies of gametocyte burdens following therapy may be the
least informative approach but certainly represent the most
accessible means of analysis. As Butcher (35) pointed out, the
presence of gametocytes and their densities may poorly corre-
late with the variable of interest, i.e., infectiousness to mosqui-
toes. Nonetheless, a demonstration of the time required for the
elimination of gametocytemia may provide a basis for useful
comparisons among drugs. Pukrittayakamee et al. (177) re-
cently compared times to elimination of patent P. vivax game-
tocytemia among 349 patients treated with 16 different thera-
pies. The demonstrated very rapid elimination of gametocytes
by both artesunate and artemether (1 to 2 days) provides
reassurance of the ability of this class of drugs to reduce the
risk of transmission after therapy. Nacher and colleagues (153)
reached essentially similar conclusions by analyzing 1,487 pa-
tients with vivax malaria treated with either chloroquine or
artesunate.
RESISTANCE AND CONTROL OF VIVAX MALARIA
The neglect of vivax malaria over the past decades positions
this parasite for a high probability of persistence in the face of
attempts to attack it with currently available tools. The outlook
for successful intervention against dormant hypnozoites looks
especially bleak. This weakness may be as operationally crip-
pling to control efforts as having no access to insecticides, bed
nets, diagnostics, or chemoprophylactics. Primaquine repre-
sents our only currently available weapon against the hypno-
zoite reservoir. That drug, in service for almost 60 years, may
be failing and may not work as prescribed; recommended reg-
imens require 2 weeks of daily dosing; and the drug may cause
potentially fatal hemolytic anemia in some people with a
G6PD deficiency. We do not know how the drug works, if it
works, how it fails, or how it threatens G6PD-deficient persons.
The failure to improve or replace primaquine secures the po-
sition of vivax malaria as a persistent and severe challenge to
public health. The recent expression of the sentiment that we
possess the tools to eradicate malaria has been made without
consideration of the problem of vivax malaria.
Control or elimination may require the deployment of fixed-
dose combined therapies that are effective against drug-resis-
tant P. falciparum and P. vivax isolates, including the liver
stages of the latter and very likely the sexual blood stages of
both. The effectiveness of therapeutic practice in areas of en-
demicity will not bear up under the weight of complex and
sometimes toxic regimens for each species and stage of plas-
modia. The challenge to field such a medicine includes safety
among people lacking access to screening against contraindi-
cations. The absence of such a tool argues against the ex-
pressed adequacy of available tools for control, elimination,
and certainly eradication.
Mass drug administration (MDA) is the practice of distrib-
uting therapy for malaria to all people in a given area regard-
less of symptoms or any diagnostics. The appropriate applica-
tion of MDA combined with other control strategies has been
a highly effective tool. The practice fell into disfavor for de-
cades, largely thanks to what proved to be inappropriate MDA
strategies like the distribution of table salts containing antima-
larial drugs. Greenwood (91) recently described the attributes
of an appropriate application of MDA, and the discussion is
highly relevant to the control and eradication of vivax malaria.
In the absence of a transmission-blocking vaccine, MDA may
be the method of choice for ensuring that asymptomatic indi-
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viduals in a given population do not infect mosquitoes before
seeking treatment.
The ideal drug or set of drugs for MDA will be delivered as
a single dose with assurance of reasonable safety in the absence
of clinical or laboratory screening for contraindicating risk
factors. The drug(s) will have efficacy against sexual and asex-
ual forms (including liver) and will persist in the bloodstream
at protective levels for at least 2 months. The latter character-
istic permits the killing of parasites that are resident in
anopheline hosts at the time of MDA, i.e., delivering the par-
asites into a host population that remains inhospitable to par-
asite development for a period that exceeds the life span for
most anopheline vectors. Such a drug(s) does not yet exist.
That may be a consequence of severely constricting technolog-
ical barriers or the failure of the community of drug developers
(private and public) to conceptually reach beyond singular
therapeutic goals for specific drugs or combinations of
drugs. It is at least safe to say that few institutions have
come to the development table with the goal of fielding a
safe and effective agent of MDA for the elimination of
malaria from a population.
One drug, perhaps unwittingly, has approached this ideal.
Tafenoquine has shown activity against all stages of plasmodia
at therapeutic doses and has a very long plasma half-life that
exerts effective chemoprophylaxis for 2 to 3 months (201). It
remains at least conceptually possible that tafenoquine may
provide the ideal tool for MDA and eradication operations
(165). However, at least preliminary clinical evidence suggests
that tafenoquine may not be safe for people with G6PD defi-
ciency. That would rule out significant proportions of many
endemic populations including all women who happen to be
pregnant at the time of MDA. 8-Aminoquinoline toxicity to
G6PD-deficient persons may thus be the single greatest obsta-
cle to the fielding of the ideal agent of MDA.
More than 50 years after the linked discoveries of both
primaquine and G6PD deficiency, an understanding of the
mechanism of that toxicity and how to cope with it in drug
development remains elusive (32). The neglect of this specific
and relatively simple biochemical problem, as one part of the
far-broader neglect of P. vivax, may prove more costly than all
others. It may be the primary obstacle to advancing from where
we stand today, with a mixed bag of variably safe drugs that are
effective against some stages or species but not others, to
fielding the ideal antimalarial therapy for MDA. Fielding such
a therapy would almost certainly deliver a measurable blow
against plasmodia, and it would lend credence and confidence
to a serious discussion of global eradication. However, we are
currently burdened under drug testing, evaluation, and licens-
ing paradigms designed and equipped to cope with falciparum
malaria. The far more nuanced problem of P. vivax may re-
quire renovation of that infrastructure.
FUTURE PERSPECTIVES
Vivax malaria more seriously threatens more people than
has been historically appreciated. The inadequacy of the avail-
able analytical and therapeutic tools for coping with this threat
constitutes the fallout of a long neglect. Work must focus on
addressing these gaps in order to field tools that are capable of
impacting the huge burden on public health imposed by P.
vivax. The following research priorities represent the means to
a very wide range of urgently needed research products in
clinical medicine, biology, genomics, immunology, pharmacol-
ogy, and epidemiology: development of geostatistically robust
means of virtual real-time mapping of the risk and burden of
vivax malaria; discovery of a practical means for the continuous
cultivation of P. vivax in vitro; discovery of a practical means
for generating viable hypnozoites in tissue culture systems;
validation of practical in vitro techniques for ascertainment of
sensitivity of P. vivax blood and liver stages to drugs; validation
of practical in vivo techniques for ascertainment of sensitivity
of P. vivax blood and liver stages to drugs; establishment of
preclinical research centers having access to infected patients,
suitable nonhuman primates, and insectaries for anopheline
mosquitoes; establishment of clinical research centers in non-
endemic areas which are capable of routinely and safely con-
ducting human challenge trials with P. vivax sporozoites and
blood stages; and establishment of clinical research centers
having access to patients with vivax malaria who are not ex-
posed to reinfection during long periods of follow-up.
The creation of these essential tools may be required for the
discovery, clinical evaluation, and licensing of a single, fixed-
dose combination of drugs that is capable of the safe and
well-tolerated elimination of all stages of falciparum and vivax
malarias when administered over a brief period without the
necessity of clinical supervision. The same assets would also
prove essential to parallel and vitally important efforts to field
practical vaccines.
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